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Development of lung cancer mortality in the European Union from 1980 to 2006 
Abstract 
This master thesis is devoted to study development of lung cancer mortality in the European Union 
from 1980 to 2006. Through the past two decades cancer was significantly increasing cause of mortality 
and major public health problem in Europe. Lung cancer remains the most frequent cause of deaths 
among other form of malignant neoplasms. Mortality development from lung cancer and other malignant 
neoplasms significantly differentiated between Western and former communist countries of Europe. Over 
the last two decades lung cancer mortality substantially reduced among males, while in females it was 
rapidly increasing. Elderly people over age 65 are the most numerous populations suffering from lung 
cancer. Everyone knows that tobacco smoking is major risk factor which contributes to lung cancer, but 
nevertheless, people continue to smoke. Despite the measures taken against tobacco, smoking prevalence 
remains high in the various countries of the European Union. 
Keywords: The European Union, malignant neoplasms, lung cancer 
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1.1 Problem definition 
The diseases which were widely spread in ancient times and in the middle ages, nowadays are rare 
and almost do not exist in developed countries (For instance: plague, cholera, typhus etc). However, 
there are some of them which in turn were widely spread in certain periods and became a serious 
problem for a variety of countries nowadays, such as malignant neoplasms.  
The Union for International Cancer Control states that: “Every year in Europe, cancer kills 
about 2 million people and more than 3 million new cases appear. Almost 6 million people are 
currently living with cancer. Cancer mostly appears in prostrate and lung within men and in woman’s 
breast. It can also appear in colon and rectum in both cases. Cancer is responsible for more than one 
death in four. Tobacco, diet and infections causes more than 40% of cancer deaths in Europe.” (A. 
Anderson et al. 2004:16). 
         In addition to that: “Lung cancer is one of the most hazardous threats that increase mortality 
risks in population of Europe, as for several decades lung cancer continues to be the main factor of 
males’ mortality in Europe, approximately 280 thousand deaths per year. Moreover, colorectal cancer 
causes nearly 98 thousand deaths per annum” (Tyczinski et al. 2004:599).  
         Lung cancer is considered to be the most problematic disease which still hugely affects the 
health of European population. It is well known fact that smoking is the key reason for lung cancer. 
Nevertheless, people are continuing smoking. The last decades show that cancer was mainly caused 
by tobacco smoking and unhealthy lifestyle. The proportion of elderly population is also increasing 
which in turn may result in doubling the number of new cases by 2020, particularly in Southern and 
Eastern Europe.  
According the estimates (1995), 90% of men’ and 60% of women’ lung cancer mortality were 
caused by tobacco smoking in the European Union. Estimated results could already been considered 
as an epidemic. If in the first half of 20th century features of epidemic were observed within males 
only (because it was rarely spread among women), while in the second half of the 20th century, 
smoking habits increased among women living in Northern Europe, spreading furthermore to 
Southern and Eastern Europe. (Bray, Tyczynski and Parkin 2004:96).  
Maxat Kulzhanbekov: Development of lung cancer mortality in the European Union from 1980 to 2006 12  
Rapid increase of lung disease negatively affects economic burden of European working age 
population. It influences the life expectancy of people and has features of epidemiologic misery. 
Hence, tobacco smoking ceased to be solely the medical problem. It has been widely studied among 
various non-medical specialists as well. Intensive pace of industry development negatively affects to 
the eco-biological system of the European countries. Therefore, population of European countries is 
facing today very complicated and at the same time concrete task of struggling lung cancer (Palmer 
1986:297). 
This problem can not be solved by total eradication of lung cancer; however it can be solved by 
the decrease or stagnation of the lung cancer development.  
1.2 Research goal and objectives  
The aim of the diploma thesis compiles from gathering comprehensive data and analysis of data about 
the trends of lung cancer mortality within the European Union. For the detailed research of lung 
cancer mortality, we have chosen 24 countries of the European Union for the period from 1980 to 
2006. Hence the following objectives are relevant: 
 To identify the level of lung cancer mortality among the European Union countries; 
 To analyze lung cancer mortality by sex differentiation among the European Union countries; 
  To provide descriptive analysis for the causes leading to the growth and spread of lung 
cancer mortality; 
 To describe in detail what kind of measures are taken by the European Union to maintain and 
stagnate lethal cases caused by lung cancer.    
1.3 Relevance of this study 
The importance or relevance of this work is that many European countries consider lung cancer 
mortality as one of the crucial social diseases nowadays. Tobacco consumption is the main factor of 
mortality risk in lung cancer development. In 90% of cases of lung cancer mortality of men and 60% 
cases of women are related to tobacco smoking, hence contemporary societies challenge this as a 
sharp problem and struggles with tobacco smoking (Simonato et al. 2004:886). In particular, massive 
spread of tobacco smoking has involved young age groups into this problem. Bad habits affects 
negatively to the society in general and personal living conditions. At the moment it has become 
global scale problem. The main factors of such wide-spreading of this bad habit are low price for 
tobacco, wide access and lack of restrictions in legislation regarding the advertisement of tobacco 
based production. Lung cancer is malignant neoplasm disease which is clearly proved to be caused by 
tobacco smoking. In early 50’s it was determined that smoking, especially cigarettes are among the 
most spread cause of lung cancer. The incidence of lung disease among women (whose smoking 
habits were not generally so frequent and lagged men’s smoking till the end of the Second World War 
and after war period) is increasing especially in higher age groups (Blaine and Reed 1994:536). 
It should be noted that the increase of malignant neoplasms of the lung is directly related to 
cigarette consumption and the number of smokers. Until society does not take steps to minimize 
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exposure to carcinogenic substances in the form of tobacco and other risk factors, lung cancer will 
remain the most significant and serious demographic problem in the European Union. It concerns not 
only Europe, but all other continents as well. Therefore, relevance of this study cannot be 
underestimated. 
1.4 Structure of the thesis   
Structure of the thesis consists of seven chapters. The first chapter explains the main problems, goals 
and objectives as well as the importance of thesis. The second chapter focuses on reviewing relevant 
literature, which describes in details the importance of thesis. The second chapter covers description 
and development of lung cancer from historical point of view. The third chapter describes the theory 
of the "Epidemiological transition", defining its terminology, basic facts and development stages. The 
first three chapters cover theoretical part of the thesis. The forth chapter deals with research questions 
and also stipulates the research hypotheses. The main issue to be covered is to explain to what extent 
lung cancer mortality will intensify and what human beings will do with this degenerative man-made 
disease (e.g. tobacco smoking). The fifth chapter describes the quality and accessibility of data on 
mortality from lung cancer and all malignancies. In addition, this chapter focuses in detail on all the 
basic methods of calculating, under which research was conducted. Reliability assessment is also 
under scope of this study. The sixth chapter covers major risk factors of lung cancer and prevention 
measures. The final chapter is divided into six broad analyses parts. The first two parts examines the 
overall mortality from circulatory diseases and malignant neoplasms. The third part widely explains 
gender differences in mortality development from the most frequent form of malignant neoplasms. 
The forth part describes development of lung cancer mortality. The fifth part illustrates the gender 
differences in the selected age-groups caused by lung cancer mortality. The sixth part is devoted to 
cluster analysis which allows identifying groups of countries in terms of lung cancer mortality. In the 





















2.1. Overview of the literature 
Investigation of deaths from malignant neoplasms in the European Union remains a major and 
polemic topic. Over the past two decades a lot of studies have been conducted and many scientific 
articles are written about the situation of mortality from lung cancer. Demographers of many 
European countries continue to discuss them in “hot disputes”. Lots of interesting works were written 
on theme of mortality from lung cancer in modern literature.  
The scientific article “Lung cancer mortality patterns in selected Central, Eastern and Southern 
European countries” which published in 2004 is another source to be retrieved. Such authors like 
Jerzy E. Tyczynski, Freddie Bray, Tiiu Aareleid, Miriam Dalmas, Juozas Kurtinaitis, Ivan Plesko, 
Vera Pompe-Kirn, Aivars Stengrevics and D. Maxwell Parkin addressed the problem of the 
significant impact of tobacco on the health of European citizens. Through comparative analysis, they 
attempted to identify significant differences in mortality patterns among men and women. Age-
standardized mortality rates were calculated for all ages combined and for age groups 20-34, 35-44, 
45-54, 55-64, 65-74 and 75 and over. A joint-point regression analysis was established to ensure the 
calculation of the annual percentages and to identify the time trends where significant changes are 
occurred. According to obtained results the largest proportion of lung cancer mortality among males 
was recorded in Poland and Cyprus (34.6% and 33.2%, respectively), while the lowest proportion was 
in Slovakia (27.6%) and Slovenia (27.3%). Mortality rates was extremely high in Hungary (ASMR = 
86.2 deaths 100 000 persons) and Poland (ASMR =71.5 deaths per 100 000 persons), whereas in 
Malta it considered low (ASR 45.9/100.000 persons). In Cyprus lung cancer was the second most 
common cause of death among neoplasms (after breast cancer), while in the Czech Republic, 
Hungary, Poland, Slovakia and Slovenia lung cancer was remained the third common type of 
neoplasm after breast and colorectal cancer. The highest proportion of lung cancer deaths were 
recorded in Hungary (12.8%) and Poland (10.1%) and the lowest proportion are found in Malta 
(4.6%) and Lithuania (6.4%). One of the highest mortality rates among women was considered in 
Hungary (ASMR=20.0 deaths per 100 000 women), the Czech Republic (ASMR=11.5 deaths per 100 
000 women) and Poland (ASMR=11.3 deaths per 100.000 women), whereas the lowest remained in 
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Malta (ASMR=4.8 deaths per 100 000 women) and Lithuania (ASMR=5.5 deaths per 100 000 
women). The authors emphasized that cigarette smoking among young people continues to increase. 
In West Europe around 2/3 of smokers begin smoking before the age of 18 and 1/3 before the age of 
16. Cigarette smoking was prevailing not only in candidate states, but also among EU member states 
(for example Germany and Spain). The authors suggest that carcinogenic substances which contained 
in tobacco smoke are the most dangerous, that lead to cancer of the lungs, therefore, cessation of 
tobacco smoking is the best way to avoid getting lung cancer. In this regard, they suppose that lung 
cancer mortality can be reduced only through effective tobacco control policies and preventive 
measures (for example screening) that will help to identify disease at early stages. 
 Published in 2007 by Oxford University press the article “Convergence of male and female 
lung cancer mortality at younger ages in the European Union and Russia” is devoted to lung cancer 
mortality and tobacco smoking epidemic which the most serious single public health problem in 
Europe. In this paper authors (Witold Zatonski, Marta Manczuk, John Powles and Eva Negri) discuss 
the gender differences in mortality development from lung cancer and the most important causes 
contributing to the emergence of this disease. For comprehensive investigation they selected 15 EU 
countries (mainly from Western countries) and the ten new EU members in Central and Eastern 
Europe plus Russia (as a country belonging to the Eastern Europe). The age-standardized mortality 
rate was used to estimate lung cancer mortality at ages between 20 to 44 years, which were obtained 
separately for 26 countries. According to obtained results lung cancer mortality among men and 
women significantly decreased in France and the Netherlands. Also, mortality patterns of the male 
population substantially reduced in Bulgaria, Russia, Poland, Slovakia, Czech Republic, Hungary, 
Austria, Germany, Luxembourg, Denmark, Sweden, Ireland, Greece, and the Baltic States. The most 
striking example is the United Kingdom, mortality significantly decreased in both sexes. Portugal was 
the only country where the smoking epidemic was significantly high among both sexes. In Sweden, 
mortality from lung cancer remained high among men aged over 65 years. Authors suggest the 
necessity of establishing valid and effective monitoring system for smoking prevalence. However, the 
most constitutive way is to implement effective tobacco control measures to stop and reverse the 
increasing trend in tobacco smoking among young people in Europe. 
The article “Lung cancer mortality trends in 36 European countries: secular trends and birth 
cohort patterns by sex and region 1970-2007” which published in 2009, based on the main cause of 
lung cancer - smoking. Freddy lan Bray and Elisabete Weiderpass describe recent temporal patterns of 
lung cancer mortality in the European region as well as structural differences by sex and age. To 
achieve comprehensive result an aggregated age-specific and age-standardized rates were calculated. 
According to geographical variations, lung cancer mortality was significantly differentiated among 
European countries. The highest rate was recorded in Hungary, while the lowest in Nordic countries 
(e.g. Sweden). Lung cancer mortality rates among females considered high in Denmark and Iceland. 
In the mid of 1990th mortality patterns of the female population significantly increased in Eastern 
Europe. Substantial decline of the male mortality was recorded in the Czech Republic and Ukraine. 
Initially, mortality from lung cancer was the lowest in Romania, but over the last decade considered to 
increase. In contrast to males, mortality development among females was significantly high in 
Hungary, Bulgaria and the Czech Republic. Lung cancer mortality was the most frequent in the age-
group 20-44. Mortality patterns from lung cancer were rapidly increasing in France, the Netherlands 
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and Spain. The authors assumed that the generation of women born between 1900 and 1960, are the 
most vulnerable to lung cancer. Significant differences in lung cancer mortality among neighboring 
countries are largely depended on smoking level. Authors emphasized, that prevalence of smoking in 
women is one fourth that of men. Among teenagers smoking prevalence is about one fourth of all 
smokers. According to the WHO estimates, in the 20th century, smoking killed about 100 million 
people, if appropriate measures against anti-tobacco activities will not be taken in 21st century it 
probably could kill one billion people. Researchers hope that the WHO’s program MPOWER 
undertaken in 2008 against tobacco smoking, will in turn prevent the increase in mortality from lung 
cancer in forthcoming decade. 
 The medical article “Lung cancer in the elderly – increasing epidemiological problem of the 
21st century” which published in 2005 in co-operation with Batura-Gabryel and Foremska-Iciek, 
focused on seniors (65 year old) who are the most numerous population suffering from lung cancer. 
Article describes that risk of morbidity and mortality increases with the aging process. Researchers 
conclude that the risk of death among cigarette smokers is much higher (33 times) than in none 
smokers. Facts represent that screening programs and medical treatments in the early stages of clinical 
advance make it possible to avoid surgical intrusion. The cause of many adverse outcomes of 
treatment of lung cancer among the elderly is a consequence of late diagnosis of the disease. 
Researchers believe that the treatment of elderly people depends on the stage of disease. The authors 
believe that lung cancer mortality can be significantly reduced through the implementation of 
preventive measures such as non-smoking, healthy lifestyles and timely diagnosis, which in turn will 
treat and even eliminate the disease. 
  Published in 2010 by the European Union in the framework of the Public Health Program the 
article “Determinants of smoking initiation among women in five European countries: a cross 
sectional survey” is devoted to women’s smoking tendency. The main goal of the authors (D. L. Oh, 
J. E. Heck, C. Dresler, S. Allwright, M. Haglund, S. S. Del Mazo, E. Kralikova, I. Stucker, E. 
Tamang, E. R Gritz and M. Hashibe1) is to determine why women start smoking and what factors 
may contribute to this. To achieve a comprehensive results and within program “Women in Europe 
against lung cancer and smoking” (WELAS) Project cross-sectional survey was applied. A total 5,000 
adult women from France, Ireland, Italy, Czech Republic, and Sweden were interviewed, with 1,000 
from each participating country. All participants were asked questions concerning demography, views 
on smoking and tobacco addiction. In addition, current and former smokers were interviewed. Two 
following methods were used:  logistic regression, to analyze ever versus never smokers, and linear 
regression, to analyze the age of smoking initiation. The results showed, if a family has at least one 
person (for example: father, mother, uncle or brother) who smokes, this contributes to smoking. In 
particular, 62.3% of respondents answered that the most frequent reason for smoking was a friend. 
The average age at which people start smoking was 18.2 years, while 80% started smoking before age 
20. Thus, the highest rates of young initiators were recorded in Sweden with 29, 3% who started 
smoking at the age of 14-15 and 12.0% at age 14. Relatively low level of young smokers was in the 
Czech Republic with 13.7% of women who began smoking at the age of 14-15 and 1.4% women who 
started smoking at the age of 14. The researchers concluded that among European women, friends, is 
the main factor influencing on smoking initiation, especially among young women. 
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In abovementioned, many researchers argue that one of the most important elements in the 
study of lung cancer mortality should be given to the problem of tobacco smoking as a major risk 
factor contributing to the emergence of a malignant tumor.  
2.2 History and description of disease 
Throughout the existence of the humans, death remains unrepeatable and very sensitive natural 
phenomenon in society. Mortality as an inevitable process of the human beings has always attracted 
attention of scientists. The death of any human organism is the result of interaction between the two 
groups of factors: endogenous, generated by the internal development of the organism, and exogenous 
associated with the action of the external environment. They are combined differently to each other, 
exogenous and endogenous factors that shape the lethal case. Within the development of medicine and 
technologies social control of mortality remarkably increased, society has real prospect to impact on 
its endogenous factors. In economically developed countries of Europe the priority is to reduce 
mortality from the influence of exogenous factors, which leaves its imprint on the problem of 
malignant neoplasm. Many thousands of scientists for hundreds of years have been trying to 
understand its causes and find ways for its prevention and treatment. What is a malignant neoplasm 
and how to understand it? To explain this terminology we will attempt to determine what cancer is.  
Cancer – is tumors whose features are most often (in contrast to the properties of benign 
tumors) make it extremely dangerous for life of organism, which gave a reason to call it “malignant”. 
This can also be characterized as a group of diseases caused by the uncontrolled multiplication of one 
or more cells that are multiplying in numbers occupying more space and forming a tumor. Each of 
them affects the man in his essence, irrespective of which body disease appeared initially. Cancer is 
very complex disease, speaking only by the affected organs. As the nightmare of our time, cancer 
affects not only the sick directly, but also society as a whole. More than half of patients die, despite 
the fact of the development of medicine, the number of deaths from cancer is substantially increasing 
(Kardinal and Yarbro 1979:396). 
Cancer affects all nations with no boundaries and restrictions. One of the first sources of 
existing cancer tumors had found in the fossil bones of the Neolithic times, as well as in the bones of 
American Indians living in pre-Columbian era. Cancer was first described in an Egyptian papyrus of 
about 1600 BC In the papyrus several forms of breast cancer are described. It also reports that the 
disease has no cure. The name "cancer" is derived from the term "carcinoma" which was imposed by 
Hippocrates (460-370 BC) and signifies the malignant neoplasm with perifocal inflammation 
(Kardinal and Yarbro 1979:396) 
 Since the early 20th century, the frequencies of cancer have increased. This is probably due to 
improved diagnosis, which allowed identifying many cases that previously would have remained 
undetected. However, another genuine reason is an increase in morbidity due to increasing proportion 
of older people in the population who likely have cancer more than any other age groups (Andreeva 
and Krasovski 2004:22).  
The dynamics of morbidity and mortality from cancer shows a steady increase of this pathology 
in many countries. Malignant neoplasms ranked second most common causes of deaths after 
cardiovascular diseases.  
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It is significant that in the economically developed countries, cancer is found most often. The 
explanation to this is better diagnosis and preventive measures as screening or higher proportion of 
elderly people. Cancer is degenerative disease and most frequently found in people of higher ages. 
However, there are some types of cancer, which often occurring in young people. On the other hand - 
even traditional medicine proves that some types of cancer such as lung cancer are uniquely related to 
living standards and environmental characteristics of our civilization with no respect to age groups. In 
the context of the intensive growth of cancer worldwide, the society is carrying much effort to identify 
high-risk neoplasm. The most dangerous among them is lung cancer. 
2.3. What do we know about lung cancer?  
Lung cancer is a tumor that develops from the epithelium of the affected lung. Despite the qualitative 
progress of medical technology, mortality from this disease is high. Currently, in developed countries, 
lung cancer is the most common form of cancer among men and remains the major health and socio-
economic problem. The most important factor contributing to the emergence of lung cancer is 
smoking. As everyone knows, cigarette smoke contains large amounts of carcinogenic substances. 
Prolonged exposure to carcinogens in long-term leads to a violation of the structure and function of 
bronchial epithelium, metaplasia of columnar epithelium into stratified squamous and contributes to 
malignant tumor (Uglov 1959:11) 
Until the twentieth century, lung cancer was extremely rare disease. In 1989, the world medical 
literature reported only 140 cases of this disease (Andreeva et al, 2004). In the early decades of the 
twentieth century, doctors were eager to look at this type of cancer believing that they might not have 
another chance to see it again. In 1912 the first survey on this subject has been prepared on the basis 
of 374 cases of lung cancer. Isaac Adler noted that malignant neoplasm in the lungs is "very rare form 
of" cancer which progressed in organism rapidly. This was confirmed by European annual conference 
in 1923 at the German Association of Pathology. Initially, researches had doubts on the accuracy of 
the diagnosis. At the same time various hypotheses were proposed about the causes of this 
phenomenon, which included air pollution, vehicle exhaust, the increase in the number of X-ray 
studies, and even exposure to the action of poisonous gases during World War II (Andreeva and 
Krasovski 2004:21). 
Establishing the link between cigarette smoking and cancer was complicated by a large time 
interval (20 years or more) between the start of smoking and the appearance of symptoms. 
Nevertheless in 1912 Adler apparently one of the firsts suggested that cigarettes may be causing the 
epidemic of lung cancer. In early 1920's many researchers started to express the features of that 
disease which had associated with tobacco smoking. But the first quantitative analysis supporting this 
hypothesis was conducted by Doctor Fritz Likint from Dresden who in 1929 showed that patients with 
lung cancer tended to be smokers. In 1939 a doctor from Cologne, Franz Hermann Muller has the 
world's first epidemiological study on the relationship of smoking with lung cancer on the principle of 
case control and concluded that tobacco is the main cause of the epidemic. Studies carried out a little 
later in Krakow, Vienna, initiated German researchers to believe into the relationship of tobacco 
smoking with lung cancer as well determined and undisputed (Andreeva and Krasovski 2004:22). 
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Currently lung cancer is the most commonly diagnosed type of cancer worldwide. Lung cancer 
is more common in developed countries than in developing countries. This is due to the fact that lung 
cancer in average develops rather late in higher ages and for its significant prevalence greater life 






























Theoretical and conceptual framework 
3.1. Basic Concepts 
Basic concepts and terminology are used from multilingual demographic dictionary (United Nations, 
1958), its English version, the World Health Organization, Wikipedia and other official sources.  
Master thesis covers the concept of mortality development. Mortality is a process of extinction 
generation consists of many individual deaths and occurring at different ages. It analyzes the mortality 
(deaths) in both national and regional levels. Medical authorities use mortality statistics for 
monitoring and improving their performance. Herein the following terminology is given.  
Death rate – a number of deaths occurring in a population during a given period of time, as a 
proportion of number in population. Usually the mortality rate comprises death from all causes and it 
expressed as death per 1000 persons. A disease caused death (age or sex) is reported as death per 1000 
people of the specified time. The mortality rate might be standardized when comparing mortality rates 
over time, or between countries.  
Age standardized mortality rate – is a weighted average of the age specific mortality rates per 100 
000 persons, where the weights are the proportions of persons in the corresponding age groups of the 
WHO standard population.  
Cancer – is a class of diseases in which a cell, or group of cells display uncontrolled growth.  
Lung cancer – is a disease of uncontrolled cell growth in tissues of the lung. This growth may lead to 
metastasis. The vast majority of primary lung cancers are carcinomas of the lung, derived from 
epithelial cells.  
Breast cancer - is cancer originating from breast tissue, most commonly from the inner lining of milk 
ducts or the lobules that supply the ducts with milk. 
Bladder cancer refers to any of several types of malignant growths of the urinary bladder. It is a 
disease in which abnormal cells multiply without control in the bladder. 
Stomach cancer - (also called gastric cancer) can develop in any part of the stomach and may spread 
throughout the stomach and to other organs; particularly the esophagus and the small intestine. 
Colorectal cancer - also called colon cancer or large bowel cancer includes cancerous growths in the 
colon, rectum and appendix. Colorectal cancers arise from adenomatous polyps in the colon.  
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Prostate cancer - is a form of cancer that develops in the prostate, a gland in the male reproductive 
system 
3.2 Relevant  theories and basic facts 
Basic principles of epidemiological transition and its relation to the demographic transition was well 
described by the 20th century demographers such as Omran, Caldwell, Philips1. Currently, the 
concept of epidemiological transition can be considered as the basic theoretical model that explains 
the change in morbidity and mortality. 
Demographic factors of mortality traditionally divided into two groups: endogenous (such as 
natural aging, inherited diseases, birth defects and other factors due to biological characteristics of the 
human body and its heredity) and exogenous (related to the influence of the environment: accidents, 
injuries and poisoning, infectious and parasitic diseases, acute respiratory diseases and digestive 
system and some others). The theory of epidemiological transition is the attempt to distinguish 
endogenous and exogenous factors of mortality, which in detail explains trends occurred and are 
occurring in the evolution of mortality (Demoscope, 2004). Thus, Urlanis2, who were not among the 
supporters of the concept of epidemiological transition, in his work "Evolution of life-span" shared 
factors of mortality by the internal and external causes. Attempts to separate the causes of death in the 
endogenous and exogenous can be found in several studies of Bourgeois-Pichat3, where a group of 
exogenous causes attributed infectious diseases, respiratory diseases and injuries, and to endogenous - 
all other causes of death (including cardiovascular disease and neoplasms).  
Throughout human history there have been great quantitative and qualitative changes in the 
mode of death. In terms of demographics, these changes can be regarded as one of struggle with 
premature mortality, an attempt to bring life expectancy to the biological life.  
For a few millennia Earth was dominated by so-called traditional type of mortality. Life 
expectancy in almost all regions did not exceed over 35 years. "The normal mortality rate" is 
determined by external conditions of the human environment: external causes associated with various 
adverse natural disasters, violent deaths and all sorts of accidental cases, as well as the high 
prevalence of various infectious diseases. There was also extraordinary increase in the mortality 
caused by epidemics (plague, cholera, and smallpox) and hunger, as well as the numerous wars. For 
the first time the concept of epidemiological transition was launched in 1971 by the American 
demographer Omran to explain the reasons and regularities of changes in morbidity and mortality by 
cause in different populations. The very essence of the concept of epidemiological transition is in the 
approval of a radical change in the structure of mortality by causes, when to change prevalence of 
exogenous causes of death came to the primacy of endogenous and quasi- endogenous. The beginning 
                                                 
1Omran A. R. (1971). “The epidemiologic transition”. Milbank Memorial Fund Quarterly, 49, 1,509 – 538.  
 (1977) “Epidemiologic transition”. U.S. Population Bulletin. 32.  
Caldwell J.C., (2001), Population health in transition. Bull World Health Organ 2001; 79:159–70. 
Phillips, D.R. (1994). Health and Development, Routledge, London, 336 pp.  
2 Urlanis B.C. (1978), Evolution of life-span. Publisher: Statistics. 
3Bourgeois-Pichat, J., (1984),"Mortality Trends in the industrialized countries," Mortality and Health Policy, New York:      
United Nations.  
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of this historic shift, the duration of which exceeds a century, experts refer to the mid-nineteenth 
century, although the first signs of it appeared in the 18th century (Demoscope, 2004).  
The struggle of humanity for the restriction of exogenous mortality is not yet finished, but by 
the end of the second millennium, it fits with good results. Factors of mortality that were earlier 
dominant have lost their power, people are dying not from those causes and not in those ages that 
before. Medicine played a major role in combating exogenous mortality. This is particularly true with 
the development of new sanitary conditions and the new role of medicine. Open and active 
dissemination - of antibiotics significantly increased the control of many infectious diseases, 
respiratory diseases and disease of digestive system. Further achievements in medicine allowed 
reducing mortality from the impact of exogenous factors. The century period in which there has been 
such significant change was very short compared with many thousands of years, during which the 
structure of mortality has not changed. Over a hundred years truly rapid leap was done, which had 
great importance for all subsequent development (Vishnevski 2005:61).  
Important role in this process have also played socio-economic factors. As a result life 
expectancy has increased, especially in developed countries. All this has allowed reducing deaths 
sharply from epidemics and infectious diseases. Simultaneously, this led to an increase in the 
proportion of dying from circulatory diseases and neoplasms. (Demoscope, 2004) 
At first, for the comprehensive explanation, we should define epidemiological transition theory 
in the context of Western (European) experience. In essence, the theory of epidemiological transition 
implements three main phases, during which mortality and diseases are varied in humans. The first 
stage is best known as a period of famine and murrain.  
The first phase was characterized as high mortality and fertility. By reason of the high - 
infectious diseases prevalence, deaths took away a huge number of human lives. People make it 
difficult to fight against an epidemic, that’s why there were significant fluctuations, which prevented 
the sustained growth of the population. Major breakthroughs in combating the mortality during the 
first epidemiological transition has been made due to paternalist strategies for human health and life, 
based on mass prevention activities that did not require much engagement from everyone. The new 
decline in mortality, which occurred afterwards, had a different pathway (Caselli, Mesle and Vallin 
2004:2).  
  Progressively, the first stage was replaced by the second, which is termed the "age of receding 
pandemics". The second stage of epidemiological transition is characterized by reduced morbidity and 
mortality from some other exogenous causes, primarily from infectious diseases such as tuberculosis, 
gastrointestinal infections, childhood infections, etc. However, in the second stage starts increasing 
morbidity and mortality from quasi-endogenous causes, such as diseases of the circulatory system, 
neoplasms, which in this case are displaced in an increasingly young age. This increase is a result of 
increasing pollution due to the rapid and uncontrolled process of industrialization and associated 
increase in physical and psychological pressures, leading to stress and nervous breakdowns. At the 
same time mortality increased from the accidents, particularly in manufacture (Demoscope, 2004). 
The third stage of epidemiological transition characterized by overcoming the above-mentioned 
negative consequences of the industrialization process. People begin to protect environment for the 
overall improvement of living conditions of people, their conditions of work and life. One of the main 
criteria for the development of new technology is its safety, the absence or minimization of risks to 
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health and life. More people are beginning to lead a healthy lifestyle, get rid of bad habits, exercise, 
eat healthy food and follow all reasonable safety standards. Further success of prevention and 
medicine reduce morbidity and mortality from many causes. As a result, average life expectancy 
increases including rise in such an important parameter of social development, as the average 
expected age of death from most diseases (Gaylin and Kates 1997:610).  
In 1986, Olshansky and Ault4 supposed the emergence of 4th stage of epidemiological 
transition. It can be assumed that the fourth stage began only recently, which is typical for countries 
with low mortality and higher life expectancy. At this stage there is a further reduction in mortality 
from endogenous causes markedly improved prevention and treatment of congenital diseases 
associated with genetic disorders and congenital abnormality of fetal development. Infant and 
adolescence mortality continues to decline as a sign of an explicit medical progress, and mortality 
among the elderly is becoming less visible, which is caused by an aging process. It is about promoting 
lifestyles that help to reduce the risk mortality of non-infectious origin, especially cardiovascular 
diseases and cancer. Rational diet (with the reduction of fat and calories in particular), enough sleep 
and exercise, give up smoking and moderation in alcohol consumption - these healthy habits should 
lead to a lengthening of life expectancy (Gaylin and Kates 1997:610).  
Taking into account strong and weak points of the epidemiological transition concept, we have 
to emphasize, that primary success in the struggle against mortality during the first epidemiological 
transition has been made thanks to paternalistic strategies for human health and life, based on mass 
prevention activities. Possibilities of the former strategy for reducing mortality have been exhausted 
with the completion of the first epidemiological transition. The new reduction in mortality occurred 
otherwise. Humanity has come to the second stage of transition, when it took out a new strategy, a 
new type of prevention aimed at reducing the risk of death from diseases of noninfectious origin, 
particularly cardiovascular disease and cancer, as well as from accidents, violence and other similar 
reasons directly related to diseases. This strategy required more active and conscious attitude towards 
their health by everyone, so much great material costs for the protection and restoration of health, 
which in turn has helped to increase its social value. Negative events of the last two stages can be 








                                                 
4 Olshansky, S.J. and Ault, B (1986). The forth stage of the epidemiological transition: the age of delayed degenerative 
disease. Milbank Quarterly 64 (3), 355-391 
 







Research questions and hypothesis 
4.1 Research questions              
Research questions of diploma thesis are based on aforementioned goals and objectives of the sub-
chapter 1.2. Consequently, following questions are considered: 
 What are the mortality development of malignant neoplasms in comparison with circulatory 
system diseases and other causes of death? 
 What is the difference between West and post-communist Europe in mortality development of 
malignant neoplasms? 
 What is the most prevailing type of cancer among other frequent form of malignant 
neoplasms in mortality development of the EU? 
 What is the difference between West and post-communist Europe in development of lung 
cancer mortality?  
 What are the most vulnerable age-groups among men and women affected by lung cancer 
mortality? 
 What are the major risk factors contributing to the development of lung cancer? 
 What countries of the European Union are mostly prevailing in tobacco smoking?  
4.2 Initial hypotheses 
Initial hypotheses are the guesses or better say red-marks throughout the thesis on which we can rely 
on. They allow us to structure the principal importance of the thesis, which are: whether our 
hypotheses are accurate and reliable?  
 As it was already mentioned, tobacco smoking continues to remain the most serious problem in 
the world. Over the past few decades, male mortality from lung cancer was declining in many 
countries of the European Union (For example: Belgium, Finland, Italy, the Netherlands and the 
United Kingdom). However, this fact does not change the situation cardinally in a positive direction. 
Judging by recent trends, tobacco smoking increased among women. The present thesis tends to 
dispose the following hypotheses: 
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1. The recent high level of mortality from malignant neoplasms in different part of the EU (West 
and post-communist Europe) might be related to several causes such as insufficient policy  
against tobacco smoking, low retail prices for cigarettes, alcohol drinking, improper feeding 
(addicted to fast food diet), the problem of overweight, sedentary lifestyle, stress, economic 
instability (mostly in Baltic States), lack of quality equipment (screening, mammography) to 
detect oncological diseases and their accessibility to the population. 
2. Recent changes in mortality trends indicate that many European countries have made 
significant progress in the fight against circulatory diseases, while malignant neoplasms 
remain a serious problem. If mortality development from neoplasms will continue to increase, 
we can expect that these types of diseases will become the leading and the most frequent 
cause of death among males and females in the majority of the European Union countries. 
3. For several decades, mortality from lung cancer among European men can be considered as 
the most prevalent, while breast cancer remains the most frequent cause of death among 
women. However, recent changes in mortality development (particularly in Western Europe) 
show an increase of women death cases from lung cancer. Increasing trend of lung cancer 
may reflect the fact that in coming decade lung cancer will be a major source of mortality in 
both male and female population of the European Union. 
4. As has already been proved in many studies5, the risk of lung cancer development depends on 
the dose and duration of smoking: greater seniority and high consumption increase the 
likelihood of disease development. Intensity of lung cancer mortality among women has been 
increasing over the last few decades, while among men the trend is gradually declining. If 
tobacco smoking will remain high, lung cancer mortality in female population may increase. 
5. It can be assumed that lung cancer develops mostly after the age 45 and further, and for its 
development requires long life expectancy, therefore despite the negative effects of tobacco 









                                                 
5 M. T. Muñoz Sastre., E. Mullet and P. C. Sorum (1999). Relationship between Cigarette Dose and Perceived Risk of Lung 
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Jay H. Lubin and Neil E. Caporaso (2005) Cigarette Smoking and Lung Cancer: Modeling Total Exposure and Intensity. 
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Data sources and methods 
Chapter five is dedicated to data sources and research methods. Completeness and accuracy of data 
help us to get qualitative results. Methods allow us to achieve accurate results.  
5.1. Data sources 
Mortality and other demographical data for calculating trends in age standardized mortality rates in 
the European Union countries were extracted from mortality database of the World Health 
Organization () and the European Health for All Databases  (HFA-DB) (http://www.euro.who.int/) 
Data were obtained separately for males and females, by 5 year age-groups from age 0 to 85+.   
An appropriate data for the analysis were extracted for the following countries: 
Tab 1: List of selected countries of the European Union according to 
available years 
Austria 1980-2006 Italy 1980-2006
Belgium 1980-2004 Latvia 1980-2006
Bulgaria 1980-2006 Lithuania 1981-2006
Czech Republic 1986-2006 Netherlands 1980-2006
Denmark 1980-2006 Poland 1980-2006
Estonia 1981-2006 Portugal 1980-2004
Finland 1980-2006 Romania 1980-2006
France 1980-2006 Slovakia 1992-2005
Germany 1990-2006 Slovenia 1985-2006
Greece 1980-2006 Spain 1980-2005
Hungary 1980-2006 Sweden 1980-2006
Ireland 1980-2006 United Kingdom 1980-2006
 
Source: WHO Mortality database and ICD (http:/ / www. who. int/ classifications/icd/en/) 
In May 2004 the European Union enlarged into the union of the 25 member states. However, the data 
were available only for 24 countries and in most cases covers period of 1980-2006. Almost all 
countries in the European Union were used for mortality estimation, except Cyprus, Malta and 
Luxembourg, due to small population. 
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 It should be noted that several countries have insufficient data. To provide an overview of the 
recent mortality patterns of all malignant neoplasms and lung cancer, we divided all countries in two 
geopolitical regions (western countries and post-communist countries). 
 For the entire study period (1980-2006) three different revisions (8th, 9th and 10th) of the 
International Classification of Diseases (ICD) were used. The ICD is a basic normative document, 
which is used by medics and demographers worldwide. Every 10 years the document is reviewed. The 
publication consists of three volumes, which include instruction, classification and index. The aim of 
ICD is to create conditions for the systematic recording, analysis, interpretation and comparison of 
mortality and morbidity data, obtained in different countries or regions and at different times. The 
idea of developing the ICD was due to necessity of more efficient storage and retrieval of diagnostic 
data. William Farr was the first who paid attention to the importance of a standardized statistical 
nomenclature of causes of death. In 1855, Farr introduced the classification of death in the Second 
International Statistical Congress. In 1900 the ICD was firstly recognized as an International list of 
death causes. Since then, 10 consecutive revisions were published. (M. Moriyama, 1966:1277). In 
terms of availability of data on cancer, the most convenient in our study are 8th, 9th and 10th revisions. 
Due to new discoveries in medical science, many improvements have been made to the coding of the 
10th revision. Unlike the ICD-8 and ICD-9, the ICD-10 code includes greater detail, changes in 
terminology, and expanded concepts for injuries, laterality, and other related factors. The complexity 
of ICD-10 provides many benefits because of the increased level of detail conveyed in the codes. But, 
in many ways, the ICD-10 and ICD-9 are quite similar. Anyone who extracts data from 9th revision 
should be able to make the transition to coding 10th revision; therefore, despite the differences and 
innovations that contain in the revisions, the right sort of data, allow us to achieve qualitative results. 
 In order to calculate lung cancer mortality, the most frequent types of malignant neoplasms such 
as breast, bladder, colon and rectum, stomach and prostate cancer was used.  Moreover, for an 
efficient international comparison we also employed circulatory diseases and other causes of death, in 
order to give comprehensive explanations for the processes described.  
Tab 2: List of selected causes of death according the revisions of the International Classification of Diseases 
ICD codes  WHO MD codes ICD codes  WHO MD codes ICD codes  WHO MD codes
1. Circulatory diseases 390-458 A080-A088 390-459   B25-B30 (CH17) 1064 I00-I99
2.Neoplasms 140-199 A045-A058 140-239 B08-B17 1026-1047 C00-D48
MN of bladder 188 A058 188 B126 1041 C67
MN of breast 174 A054 174 B113 1036 C50
MN of colon, rectum and anus 152-154 A048-A049 153-154 B093-B094 1030 C18-C21
MN of trachea, bronchus and lung 162 A051 161-162 B101 1034 C33-C34
MN neoplasm of prostate 185 A057 185 B124 1040 C61
MN of stomach 151 A047 151 B091 1029 C16
Causes of death
ICD-8 Codes ICD-9 Codes ICD-10 Codes
 
Source: WHO Mortality database and ICD (http:/ / www. who. int/ classifications/icd/en/) 
The lack of data in some former socialist countries may be explained by reforms in healthcare system 
or they do not provide information to the WHO database due to other reasons such as lag in updating 
the registers according to the WHO standards or inconsistency with an old health care system. 
Incompleteness of data can be a reason to above mentioned problems.  During several decades post-
communist European states were under complex reforms. The collapse of communist regimes 
between 1989 and 1991 was very painful for the economy of some East European countries (for 
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example: Poland, Bulgaria, Romania and Baltic States). The new governments of Eastern European 
countries inherited many problems from its predecessors. We suppose that transition period from old 
centralized health care system to new West model was not an easy process. Therefore, it is likely that 
“some” of the statistics of the former socialist countries of Eastern Europe do not quite meet the 
requirements of WHO so era of 90’s brought significant changes in standards of gathering data.  
 Health data - figures and statistics are mandatory elements to track the situation and trends in 
health and helps to evaluate the impact of public policies and health programs. Data on mortality from 
lung cancer for the European Union were taken from the central database of the WHO, which includes 
independent, comparable and updated statistical information on key health indicators. It serves as 
principal source of information on public health in the European countries. The WHO supports the 53 
Member States in the WHO European Region in developing and sustaining their national health 
policies, health systems and public health programmes; to identify, prevent and overcome potential 
threats to health; anticipating future challenges; and advocating public health. This provides an 
important opportunity for comparison and analyses of health trends in the region, observation and 
detection of the most dangerous diseases for the population, as well as, for inducing a systematic 
policy to promote healthy lifestyles. In general, reliability and accessibility can be judged positively 
due to well-structuralized sets of data and its consistency.  
5.2. Methods 
5.2.1 Direct method of standardization 
In order to compare two or more groups with different internal age structure in epidemiological 
studies, standardized mortality rates are calculated. The method of indicators' standardization allows 
to compare the aggregated data which has different internal age structure. It consists of calculating 
new indices, based on the assumption that the internal structures of the studied populations correspond 
to the structure of the sets taken as a sample (standard).   
 Historically, in the middle of the 19th century, the need for age standardization was recognized 
before the general concept of confounding was formalized. The first idea of a truly international 
standard was suggested in 1892 by Ogle. In May, 1965 at a meeting of the International Union 
Against Cancer (IUAC) conference in London this matter was thoroughly discussed and three 
standard populations were suggested.  Each of the three proposed standards has been specifically 
designed for particular population types. One standard with a high proportion of young people was 
appropriate for making comparisons with populations in Africa. The second one, it calls “European”, 
was focused on Scandinavian populations, which contained relatively high proportion of old people 
and it was most acceptable to compare Western Europe. The third one was intended as “world” 
standard based on the experience of 46 countries. Eventually, “European” and “world” standards were 
adopted by the WHO for use in calculating age-standardized death rates. For international 
comparisons of standardized coefficients and for the state mortality statistics two types of age 
structure are used: World and European standards (Ahmad et al. 2001:4).  
Demographers and medical workers in England argued that simple crude rate was inapplicable for 
comparing population's mortality or morbidity when the age distribution of two or more regions was 
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substantially different. It should be noted that the earliest epidemiological studies of age 
standardization appeared in a publication of F. G. P. Neison in 1844.  Moreover, he clearly introduced 
two major approaches of direct and indirect standardization (Ahmad et al. 2001:4).  
 There are two possibilities of computing standardized death rates – direct and indirect. Direct 
standardization is often preferred method especially in epidemiological contexts (For example: 
analysis of cancer incidence and mortality). For comparison of overall mortality rates using direct 
standardization is necessary to calculate the number of deaths that could be recorded in this 
population if the age composition of the population coincided with the age composition of the 
population-standard. The direct standardization can be used in the study of a sufficiently large 
population, where age-specific factors in the population are stable and consistent. It should be noted, 
when the population is small, then the number of events in the target population can also be small. In 
contrast to direct standardization, indirect method is highly reliable in context of small population. 
Therefore, analyzing data of 24 countries of the European Union by direct standardization is most 
suitable.  The formula for direct standardization can be expressed as: 
SDR (Standardized Death Rate) = [Sum age groups (Mar Pas)]/Ps x 1000 
Mar is the age specific mortality rate for the region 
Pas is the number of people in the age group in the standard population 
Ps is the total standard population 
They eliminate the differences in the age composition of the population and therefore more accurately 
reflect to the relative levels of mortality in the spatial and temporal comparisons. Based on the 
foregoing, the direct method of standardization is especially useful when comparing the death rates by 
cause of death, as the standardized mortality rate from a group of causes of death is the sum of the 
standardized mortality rates from each of the causes of the group. 
5.2.2. Cluster analysis 
Before speaking regarding the results of the cluster analysis it is always good idea to understand 
cluster analysis itself. The first application of cluster analysis was found in sociology. The title of the 
cluster analysis is derived from British word cluster – “cluster” (accumulation). The first founders of 
cluster analysis were researcher Tryon, Ward and Johnson6. The big advantage of cluster analysis is 
that it allows creating decomposition of objects not only by one parameter, but also in whole groups 
i.e. clusters. Cluster analysis enables to distinguish a large amount of information, make them 
compact and visual. Currently, except statistics and sociology, it also widely disseminated in analysis 
of demographic data. For instance, in this work the cluster analysis is used for treatment and 
providing comprehensive information on trends by lung cancer mortality among European Union 
countries (Dostal and Pokorny 1991:1).    
 Cluster analysis represents a collection of statistical methods, which allow us to identify 
groups of samples that behave similarly or show similar characteristics. In any scientific activity 
classification is a fundamental component, without which the construction and testing of scientific 
                                                 
6 Tryon R. (1939), Cluster analysis. Edward Brothers, Ann Arbor, Michigan.  
   Johnson S.C., (1967), “Hierarchical Clustering Schemes” Psychometrica, 4, 58-67. 
   Ward J.H. (1963), “Hierarchical Grouping to Optimize an Objective Function”, Journal of American Statistical    
Association, 58, 236-244.    
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hypotheses is impossible. As a result of cluster analysis predefined variables form the observation 
group. Observation refers to individuals (respondents) or any other objects. Members of one group 
(one cluster) should have similar manifestations of variables, and members of different groups should 
have different variables.  The cluster analysis makes it possible to divide the entire initial set of 
indicators of conjuncture groups (clusters) on the relevant criteria, thus facilitating the selection of the 
most representative indicators.  
 To analysis of lung cancer data, the SPSS program was used. SPSS (Statistical Package for the 
Social Sciences) statistical system is a universal program that supports the process of analyzing data at 
any level and is intended to implement the complete sequence of steps of data analysis: viewing the 
data, creating tables and calculating descriptive statistics. It is important to note, that SPSS has three 
different procedures that can be used for data clustering: hierarchical cluster analysis, k-means cluster 
and two-step cluster. If we have a large data file (for example: even 1,000 cases are large for 
clustering) or a mixture of continuous and categorical variables, the two-step procedure is more 
suitable than other methods. On the other hand, if we have a small data set and we want to find 
solutions with an increase of clusters, we have to use a hierarchical clustering. K-means clustering is a 
method which aims to partition observations into k-clusters in which each observation belongs to the 
cluster with the nearest mean.  
 There are many ways in which clusters can be formed. One of the most common and simplest 
methods is hierarchical clustering. In statistics, under the term of hierarchical clustering we 
understand the method of cluster analysis which seeks to build a hierarchy of clusters. Algorithms for 
hierarchical clustering are generally either agglomerative or divisive. Agglomerative clustering starts 
with each object in a separate cluster. Clusters are combined, grouping objects every time in more and 
larger clusters. This process continues until all objects do not become members of a single cluster. 
Divisive clustering starts with all objects that are grouped in a single cluster. The main advantage of 
hierarchical clustering methods is their visibility. That’s why unlike other methods, hierarchical 
clustering led us to create a hierarchy of clusters, which can be represented as a tree structure called a 
“dendrogram”. The Dendrogram can be found as a graphical representation of results of consecutive 
clustering which implements in definition of matrix distance and with dendrogram we can graphically 
or geometrically display the function of a clustering. There are many ways to build dendrogram. In 
dendrogram objects are placed vertically on the left, the results of clustering – on the right. The 
distances or similarities, corresponding to structure of new clusters, represented by horizontal line 
over dendrogram. There are two advantages of hierarchical clustering: firstly it’s simple and a 
structure is more informative, secondly it does not require us to pre-specify the number of clusters. 
The disadvantages is that selection of merge or split points is critical once a group of objects is 
merged or split, it will operate on the newly generated clusters and will not undo what was done 
previously. Thus merge or split decisions may lead to low-quality clusters if not well chosen. 
Measure of proximity (similarity) of objects can be conveniently represented as the reciprocal 
distance between objects. The most accessible perception and understanding in case of quantitative 
traits is so-called Squared Euclidean distance. Distance is a measure of how far apart two objects are, 
while similarity measures how similar two objects are. The Squared Euclidean distance helps us to get 
the same results in terms of boundary delineation as the Euclidean distance. There is a formula that 
can be expressed as: 
Maxat Kulzhanbekov: Development of lung cancer mortality in the European Union from 1980 to 2006 31  
 








ii yx  
 
In contrast to Euclidean Distance the deriving of Squared Euclidean distance (d) between two data 
points (x) and (y) does not involve computing the square root of the sum of the squares of the 
differences between corresponding values. Clusters are divided (split) until each object will not 
appear in a separate cluster. In the method, which is installed on SPSS by default “Between-groups 
linkage” (connection between the groups), the distance between clusters is the average value of 
distances between all possible pairs of observations, one observation is taken from one cluster and one 
from another. Information needed to calculate the distance, is on the basis of all theoretically possible 
pairs of observations. When we clustering cases we must standardize the variables, therefore z-scores 
is the most appropriate way in standardizing data. We mainly use it when some similarity measures 

























Risk factors and preventive measures 
6.1. Risk factors 
The fact that effect of all carcinogenic substances on the human body in our society has long been 
known, but nonetheless, we continue to deliberately expose ourselves to many risk factors. On the 
threshold of the 21st century we have seen that not only external exogenous factors can cause harm to 
humans, but also a lot of other circumstances, to which we are exposed on our own. We suppose that 
one of the crucial factors is the poor nutrition, disease transmitted through food, and lack of safe 
access to safe food. Moreover, we can add an overweight and obesity, sedentary and immobile 
lifestyle, depression and stress that result in serious and progressive damage, which gradually affects 
the appearance of malignant neoplasms. 
Lung cancer, as well as general cancer of any location, does not occur on healthy soil. It is 
preceded by lengthy pathological processes caused by one or another etiologic factor. It is generally 
accepted that lung cancer can cause various adverse of environmental factors. Among the most 
common reasons in this regard is dust containing radioactive sub- position, chromates, or asbestos. 
We have to take into account, that one of the fundamental reasons is our everyday life, in which we 
waste a lot of time for drinking alcohol and smoking cigarettes. About all these harmful effects and 
factors we describe in details in the following chapter. 
6.1.1 Smoking 
Massive distribution of smoking has become an international issue. Smoking has been called the 
plague of the twentieth century. Tobacco smoking continues to kill more than 5 million people 
worldwide each year – more than HIV/AIDS, tuberculosis and most likely this number will grow 
(WHO, 2008). Smoking is a social problem in society, both for smoking and non-smoking part. For 
the first - the problem is to quit smoking for the second - to avoid the influence of smoking society 
and not "get" their habit, and - save your health from tobacco products. Tobacco smoking - addiction, 
one might even say drug addiction. This is one of the most common types of drug addiction, covering 
a large number of people and is home abuse.  
Many do not know that smoking, which begins with “pampering”, “desire to imitate”, “not to 
remain out of fashion”, “grow faster”, turns into an insidious habit, which is harmful to health. 
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Smoking is especially harmful to young, developing organism. It binds the will, undermines health, 
and shortens life. Cigarette smoking and all sorts of tobacco products have a negative impact on 
nearly every human organ. Smoking, regardless of the number of consumed cigarettes per day, always 
sooner or later leads to the diseases like: coronary heart disease, chronic bronchitis, pulmonary 
emphysema, bronchial asthma and finally cancer. Lung cancer is the typical disease associated with 
tobacco smoking.  Negative impact of smoking products causes 80-90% of all lung cancer death, and 
about 30% of all cancer death in developing countries, including death cancer of the oral cavity, 
larynx, oesophagus and stomach (WHO, 2002). There is evidence that the smoking among people in 
developed countries are slow declining, but burden of tobacco use is increasing in low- and middle-
income countries, and will increase more rapidly in these countries in coming decades (WHO, 2009). 
Recent statistics show that about 70% of tobacco users live in developing countries, and about half of 
the men in these countries are smokers. Smoking prevalence is lower among women than men in most 
countries, but it is important to know that approximately 200 million of one billion smokers in the 
world are women (WHO, 2010).  
Mortality due to smoking among women is still rising in many European countries and 
continues to be a serious problem. The use of tobacco among young women in countries with large 
populations is among the most ominous trends. Tobacco companies have long understood the 
importance of women and girls in the overall market for cigarettes and therefore continue to lure 
women to expand their customer base. Smoking impacts women's health in the specific way. In 
scientific literature there is quite a lot of evidence on the impact of smoking on reproductive function 
of women. The World Health Organization states that about 22 percent of women in developed 
countries and 9 percent of women in developing countries smoke tobacco. In the WHO European 
Region, 21% of women smoke: more than in any other region in the world, but still significantly less 
than the 59% of European men who smoke (WHO, 2010). 
 In addition, we must know that the risk of lung cancer declines steadily in people who stop 
smoking, after 10 years, the risk becomes 30-50% less of that in continuing smokers (Commission of 
the European Communities, 1999:7). Smoking not only causes many diseases but assists to the 
evolution or better say directly stimulates the development of disease by weakening the protective 
reaction of the organism.  
6.1. 2 Tobacco consumption   
Global consumption of cigarettes has been rising steadily since manufactured cigarettes were 
introduced at the beginning of the 20th century. While consumption is decreasing in some countries, 
more people in worldwide are smoking cigarettes (WHO, 2009).  
         The uniqueness of tobacco is that it is the only legally distributed product that causes harm. 
Tobacco continues to operate in market only due to the fact that smoking is widespread among 
diverse population groups that are strongly dependent on it. We regret to note that many people 
underestimate the deleterious effects of tobacco on health and are loyal to smoking. Also, we must 
take into account that those representatives of tobacco companies, recognizing "the possible negative 
consequences" of smoking to health, justify its existence for the benefit of economic development, job 
creation, filling the budget through taxes. 
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         This part analyzes and describes a tendency of cigarette smoking among males and females 
population of the EU countries. According to graphical indicators we have an opportunity to reveal 
not only gender differentiation in tobacco dependency, but also a distinction among all the countries. 















































































































































































1989/90 1993/94 1997/98 2001/02
Boys
 
Notes: Smoking defined as smoking at least once a week 
Source: World Health Organization (2003) Young people's health in context. Health Behavior in School-aged    
Children (HBSC) study: international report from the 2001/02 survey.  
WHO: Copenhagen, and previous editions 
Figure 1 shows that the prevalence of tobacco smoking was very heterogeneous among most of the 
European Union countries. From 1989 to 1990 the highest level (31-33%) of tobacco smoking among 
boys was observed in Hungary and Finland, while the lowest rate was observed in Sweden (15%). 
During the period from 1993 to 1994, intense smoking was observed in Latvia (33%), Belgium (32%) 
and Austria (29%). Significantly lower level of smoking habit was recorded in Italy (9%). From 1997 
to 1998 high level of tobacco smoking was observed among Latvian (37%), Hungarian (36%) and 
Austrian adolescents (30%). Only in Germany and Sweden was this level the lowest (18%) among 
other countries. In subsequent years (2001-2002) smoking among boys significantly increased in 
Lithuania (35%) and Germany (32%). The opposite trend was observed in Sweden (11%). In contrast 
to the above mentioned countries, the most favorable trends from tobacco smoking were recorded in 
Greece (14%), Denmark (17%) and Portugal (19%). 
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1989/90 1993/94 1997/98 2001/02
Girls
 
Notes: Smoking defined as smoking at least once a week 
Source: World Health Organization (2003) Young people's health in context. Health Behavior in School-aged    
Children (HBSC) study: international report from the 2001/02 survey.  
WHO: Copenhagen, and previous editions 
According to Figure 2, it can be noted that smoking habits among girls was extraordinarily high in 
Finland (32%) and Spain (27%), while in Poland it was considered low (10%). In 1993 and 1994 the 
highest levels of tobacco consumption were observed in Austria (31%), Germany (29%), Finland 
(26%), Spain (27%) and the United Kingdom (27%). Smoking patterns recorded in Lithuania (4%), 
Estonia (6%) and Slovakia (5%) were substantially lower. In 1997 and 1998, smoking remained on 
extremely high level in Austria (36%), and continued to increase in the United Kingdom (33%), 
Germany (33%), France (31%) and Denmark (29%). In Lithuania and Estonia, tobacco consumption 
was less frequent (10-12%). In the later study period (2001-2002) tobacco smoking substantially 
increased in most of the Western European countries (e.g. Austria, Germany and Spain). 
          Based on the above analysis, it can be emphasized that tobacco consumption of the young 
women was differentiated across most of the European Union countries. In contrast to the former 
communist countries (e.g. Poland, Slovakia and Estonia), tobacco smoking was the most frequent in 
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Notes: "Smoking" defined as regular daily smoking 
Source: World Health Organization (2004) European Health for All statistical databases  
(http://www.who.dk}) 
Notes: "Smoking" defined as regular daily smoking 
According to Figure 3, it can be observed that smoking prevalence is not at the same level in the 
European countries. Tobacco smoking among males was extremely high in the countries such as 
Lithuania (52%), Latvia (49%), Bulgaria (49%), Greece (47%), Estonia (45%) and Slovakia (44%), 
while the lowest level was observed in Sweden (16%). The average level of tobacco smoking was 
observed in Finland (28%), Slovenia (28%) and United Kingdom (27%). In contrast to smoking men, 
tobacco consumption among women remained low, but nevertheless, the countries with high and low 
level of smokers can be identified. Tobacco smoking among women was at the highets level in the 
following countries: Ireland (31%), Germany (30%), Netherlands and Greece (29%). The lowest 
percentage of tobacco smokers was observed the Czech Republic (18%) Italy (17%) and Slovakia 
(15%), while in Romania and Portugal it was even lower (10%). From the second half of the 90's to 
2002 smoking prevalence of the male popultion significantly increased. Based on the above analysis, 
it can be determined that  prevalence of tobacco smoking among men was observed in the former 
communist European countries (Germany, Poland, Bulgaria, Slovakia and the Baltic States) at the 
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  Source: World Health Organization (2004) European Health for All statistical databases 
Figure 4 shows a cigarette consumption of the male and female population which can be described as 
heterogeneous among the European Union countries. In 1980, the highest number of cigarettes was 
consumed by Polish (2666), Hungarian (2652) and Greek people (2271). Relatively low level of 
cigarette consumption was observed in Finland (1285cigarretes) and Portugal (1320 cigarretes). In 
contrast to previous years, cigarette consumption significantly increased in 1990. The highest level of 
cigarette smoking still remained in Hungary, Poland and Greece. Also, smoking was significantly 
frequent in Belgium (1994 cigarretes), Spain (1952 cigarretes) and Germany (1876 cigarretes). The 
lowest level was observed in Sweden (1353 cigarettes). Further development of cigarette smoking 
substantially increased the level of cigarette consumption in many European Union countries. It is 
important to note that in 2000 high levels of cigarette consumption were observed in Greece (2953 
cigarretes) Bulgaria (2792 cigarretes), Spain (2464 cigarretes) and the Netherlands (2401 cigarretes). 
Cigarrete smoking was less frequent in Sweden and Finland (902-918 cigarettes). 
 To conclude this part, it must be emphasized that smoking remains the most common and 
attractive habits among people, causing damage to both sexes and society as a whole. Smoking still 
involves almost all the segments of the population, particularly women and the youth. Over the past 
few decades smoking has significantly increased among young women in Western countries, as well 
as among men in the former socialist countries of Europe. 
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6.1.3 Passive smoking  
Evidence that passive smoking can result in serious illness or even death among non-smokers first 
appeared in the English-language scientific journals in 1974 (Colley, Holland and Korkhill 
1974:1031). Since that time, there have been literally dozens of independent scientific investigations 
of the relationship between passive smoking and a variety of health problems.  
Passive smoking - inhaling the ambient air with its products, tobacco smoke of others. Over 
4,000 chemicals have been identified in tobacco smoke, at least 250 which are known to be harmful, 
and more than 50 of which have been found to contribute to the emergence of cancer (WHO, 2009). 
Passive smoking as well as many calls it second-hand tobacco smoke (SHS) may be present in 
virtually all public places where people gather, namely, pubs, cafes, restaurants, night clubs and many 
other places. Often people do not think about the harm caused to them by tobacco smoke. Many 
people believe that cigarettes harm only to those who smoke however it is false statement. Passive 
smoking also causes organism to irreparable damage. It is necessary to know that passive smoking 
contributes to the development of diseases peculiar to smokers. The harm of smoking for people, who 
are in the same room with a smoker, arises from the fact that it is forced to absorb substances secreted 
by the so-called "side stream" smoke. The main stream of smoke gets into the lungs of the smoker, 
but the part that released into the air, inhaled by all who are nearby. Passive smoking is inevitable 
with regular stays close to the smokers. There are many facts about the effects of passive smoking on 
children's health. Infants and toddlers are particularly vulnerable to the effects of passive smoking due 
to the fact that their bodies are still in the stage of growth and formation, and because they breathe 
faster than adults (Donaldson and Gilmore 2010:180). It should be taken into account the fact that 
children are most receptive to tobacco smoke, so scientists have given convincing evidence that 
passive smoking has a lasting impact on the respiratory system of children. 
The harm of passive smoking is a key argument of the introduction of policies regulating 
smoking and tobacco products. Despite the fact that information about the danger of passive smoking 
appeared a long ago, the tobacco industry tried to sow doubt in order to prevent regulation of their 
products.  
6.1.4 Asbestos Fiber  
Asbestos is one of the most significant occupational carcinogens, which accounted for about half of 
all deaths from cancer caused by occupational circumstances (WHO, 2010). Exposure to asbestos 
occurs from inhalation of polluted air in the working environment, as well as from ambient air near 
the sources of such contamination or indoor friable asbestos-containing materials. The most exposed 
to asbestos fibers are the workers of companies engaged in thermal and acoustic insulation. Today, 
asbestos use is restricted or prohibited in many countries. Lung cancer and mezothelioma often caused 
by exposure to asbestos fibers.  
We can suppose that workers family members heavily exposed to asbestos, thus an increased 
risk of developing mesothelioma7. This might be resulted from exposure to asbestos fibers brought 
into the home on the shoes, clothing, skin, and hair of workers. Many studies have shown that the 
                                                 
7 Mesothelioma is a form of cancer that develops from the protective lining that covers many of the body’s internal organs. It 
is usually caused by expose to asbestos. 
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combination of smoking and asbestos exposure is particularly hazardous. Smokers who are also 
exposed to asbestos have a risk of developing lung cancer that is greater than the individual risks of 
asbestos and smoking added together. There is some evidence that quitting smoking can reduce the 
risk of lung cancer among asbestos-exposed workers (Vainio et al. 1993:191) Smoking combined 
with asbestos exposure does not appear to increase the risk of mesothelioma. However, people who 
were exposed to asbestos on the job at any time during their life or who suspect they may have been 
exposed should not smoke. 
6.1.5 Radon  
Let us dig into only one carcinogenic factor which could be found in almost any basement of the 
houses, contributing to the appearance of lung cancer - for radon and its short-lived decay products. 
Many people are exposed to radon in homes. The concentration of radon in the contiguous houses 
may be different, and its concentration in the same home can change daily or even hourly. Because of 
these fluctuations, estimating the annual mean concentration of radon in indoor air requires 
measurements of mean radon concentrations for at least three months. Radon gas can penetrate 
through the soil and get into the house through the pipes, windows and chimneys. Therefore, the 
amount of radon released from the earth's crust, is significantly different in the air in different 
locations around the globe. Radon gas - an invisible and odorless, but it can be detected by simple 
specialized devices.  
6.1.6 Occupational factors  
The important role in the occurrence of lung cancer is occupational factors. It is proved that the risk of 
lung cancer elevates in the workers of aluminum industry, coke, iron and steel melting in the 
underground mining of hematite, as well as among workers dealing with radioactive substances, 
arsenic and its compounds, coal tar, nickel and its compounds, rubber industry, etc (Boffetta and 
Nyberg 2003:72) It should be stressed that a respiratory system diseases and lung cancer are exposed 
not only by workers of heavy industry, but including all those who daily absorb large amount of dust. 
Thus, any carcinogenic effects such as dust particles can cause serious damage to our respiratory 
system, which turn, causes lung cancer risk.  
6.1.7 Air pollution  
There is no doubt that inhalation of carcinogenic dust was a contributing factor to the increase of lung 
cancer frequency. In fact, it is difficult to assume that thousands of tons of coal dust, bits of tar and 
resins, as well as other products of incomplete combustion, which are daily thrown into the air from 
the chimneys of factories, automobiles and diesel engines, would not damage lungs and not cause a 
chronic inflammatory process that in itself is a predisposing factor in lung cancer development, not to 
mention the direct carcinogenic effect of inhaled particles (Uglov 1959:11).  
However, existing epidemiological data on air pollution as an etiological factor of lung cancer 
indicates that air pollution is likely to affect the development of this disease, but the effect of smoking 
and occupational factors is much more visible. 
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6.1.8 Genetic predisposition 
While most cases of lung cancer are associated with smoking, genetic predisposition is still a big 
factor of disease development, supported by numerous studies8. The presence of certain lung diseases, 
particularly chronic obstructive pulmonary disease, is associated with an increased risk of lung cancer. 
It is very important to understand that individual risk factors can affect the cancer. Genes play an 
important role in our life and they control most of the processes that occur inside human body. In 
normal life, genes are capable to support cell division and growth. When damage occurs in genes - 
mutations - can develop cancer. The families which had cases of illness or death from cancer, 
especially at a young age, fall into the high-risk group. For example, a woman whose mother or sister 
had breast cancer have twice the risk of developing cancer compared to those families that did not 
have the disease. Those families, who have indicated an increased incidence of cancers, should begin 
regular screening at a younger age and pass them more frequently. Patients with genetic syndromes, 
transmitted in the family, will be determined by individual risk for each family member (Mohandas 
2001:482).  
6.2 Prevention  
The cancer prevention issue nowadays with no doubt will be considered with more attention as lung 
cancer as one of the most common cause of mortality. Disease prevention becomes increasingly 
important. Scientists around the world recognize that only the wide application of science-based 
prevention of diseases will help mankind cope with this scourge. Currently there are only two ways to 
fight against malignant tumors: prevention and diagnosis at earlier stages, which allows to "freeze" 
the cancer for many years and successfully treat it (Khuri 2003:40). Prevention of lung cancer should 
consist of two components:  
a) Under the primary prevention of lung cancer we mean a prevention of cancer by removing or 
neutralizing the impact of environmental factors and lifestyle. It is very important to quit smoking and 
avoid exposure to potentially cancer-causing substances at work. Rational diet which contents a lot of 
fruits and vegetables help us to reduce a risk of lung cancer. 
b) Secondary prevention (screening) includes lungs preventive examinations, as well as the 
treatment of precancerous diseases of the lungs. Screening Screening studies have only been done 
among high risk populations, such as smokers and workers with occupational exposure to certain 
substances. This is because radiation exposure from repeated screening studies could actually 
induce cancer formation in a small percentage of screened subjects, so this risk should be mitigated by 
a (relatively) high prevalence of lung cancer in the population being screened. ScreeningThey also 
include long-term tobacco smoking as well as those recovered earlier from malignant neoplasms. 
Observation of such patients is aiming to retrieve early forms of lung cancer for better treatment and 
prevention of lethal cases. Generally speaking, measures such as lifestyle changes and improvement 
strategies for prevention and screening can be reused to reduce mortality from this disease (Adami, 
Trichopoulos and Willett 2001:126).  
                                                 
8 Steven A. Frank (2004). Genetic predisposition to cancer – insights from population genetics. Department of Ecology and 
Evolutionary Biology, University of California, USA, p-746 
P Hutter, A Couturier, R J Scott (1996) Complex genetic predisposition to cancer in an extended HNPCC family with an 
ancestral hMLH1 mutation,  Division de Genetique Medicale, CMU, Geneve, Switzerland, p 33:636-640.  
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6.3 European policy against tobacco  
In 1987, Europe was the first WHO Region which took the initiative on five-year Action Plan for 
“Tobacco-Free Region”. Over the past period from 1987 three action plans on tobacco control were 
adopted, which set tasks related to all major aspects of tobacco control policy. In the First European 
Action Plan of “Tobacco-free Europe” (1987-199) member states developed and adopted a 
comprehensive and multidisciplinary approach in this area. It also urged countries to establish an 
effective system for monitoring and evaluating their tobacco control measures. Second Action Plan 
(1992-1996) was aimed to increase financial support and national capacity for tobacco control and 
contained a recommendation to strengthen cooperation with Central, Eastern and Southern Europe. In 
order to take more effective measures, Third Action Plan for “Tobacco-Free Europe” (1997-2001) 
was adopted on the forty-seventh session of the Regional Committee for Europe. Taking into account 
the results of the First and Second Action Plans and World Health Assembly resolutions calling for a 
comprehensive tobacco control strategies (WHO, 2002).  
 Since the adoption of the Third Action Plan approximately three quarters of European Member 
States have significantly reinforced their policies on tobacco taxation: two-thirds of countries have 
strengthened measures against smuggling; one third have introduced age restrictions on tobacco sales; 
and at least eight countries introduced a complete ban or strict restrictions on direct advertising, which 
in turn significantly improved the rules on smoking in public places. In addition, since 1997, about 
one third of Member States have created intersectoral coordinating committees, and half of them have 
adopted national plans of action on tobacco control.  
 Scientific research and successful practical examples in the European region and in other parts 
of the world suggest that, thanks to flexible, differentiated and creative strategies, tobacco 
consumption can be reduced. In turn, significantly improving health and achieving substantial 
economic gains. Recommended actions, as described in this section are based on the best available 
evidence and experience in the field of tobacco control, which was acquired in European Region. 
Tobacco control programs must be comprehensive and include at least the following components: 
• Higher taxes on cigarettes and other tobacco products; 
• Restrictions on tobacco products; 
• Bans on smoking in public places; 
• Comprehensive bans on the advertising and promotion of all tobacco products; 
• The fight against smuggling; 
• Large, direct warning labels on cigarette boxes and other tobacco products; 
• Help for smokers who wish to quit; 
• Public information and public opinion. 
1. Tobacco control advocates agree that rising taxes on tobacco products is considered to be one 
of the most effective components to induce current smokers to quit, reduce consumption of 
heavy smokers and prevent uptake by non-smokers, especially for young and low income 
people who is highly price-responsive.  Taxes need to be imposed on all tobacco products so 
that consumers cannot replace one cigarette product with another. Revenues received from 
taxes on tobacco products should be used to finance all activities related to tobacco control, 
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including health education, conducting research on regulation of tobacco and support for 
health services. 
2. Restricting access to tobacco products to young people under the age of 18 is still an effective 
way of reducing the number of teenagers and young adults who become regular smokers. One 
way of introducing restrictions on the sale of tobacco products will ensure that such products 
are sold to customers only by hand and only by the seller who has appropriate license. 
Moreover, vendors should be held legally responsible for the checking of the age of 
customers. 
3. Smoking control in public places allows minimizing and eventually eliminating the risk of 
passive smoking and helps to protect the rights of non-smokers. This law makes smoking 
socially unacceptable thing that keeps young people from acquiring this habit. It also supports 
the determination of a large number of people wishing to quit smoking.  
4. Tobacco advertising and smoking among young people is a causal link, and strict measures 
against tobacco advertising can reduce both smoking in general and among young people. In 
order to achieve substantial and rapid reduction of tobacco use, especially among women and 
men – introduction of a complete ban on advertising tobacco products needed. 
5. Apart from the fact that the smuggling of tobacco products poses a risk to public health, 
contributing to the increase of consumption, it also deprives governments’ revenues from 
tobacco taxes. Until the smuggling of tobacco products is not maintained at the national and 
international levels, the impact of other tobacco control measures will be greatly weakened. 
Stamps on cigarette packages are an effective strategy for the payment of customs duty. 
Moreover, an active international control within the European Union as well as toughening 
the laws and penalties may also be useful for reducing illegal tobacco trade.  
6. Mandated labels on tobacco products are an effective way to inform smokers about the 
dangers of smoking, which helps smokers to quit, at the same time preventing non-smokers 
not to start this bad habit. These warnings can be effective only if they contain some strong 
and direct message in a conspicuous place. In order to achieve effective results, it is necessary 
to increase the size of warnings on all cigarettes, and also to repaint all the bright colors of 
cigarette packs on less attractive colors (for example gray-green) which may substantially 
affect the consciousness of smokers. In addition, if on all tobacco products images of dead 
people or those organs that were exposed to the negative effects of carcinogens were stamped, 
it will help to discourage the demand for cigarettes. 
7. Aid in smoking cessation - is an important and promising component of tobacco control 
strategies. It should be more widely adopted program to quit smoking, developed specifically 
for men or women. It necessary to attract highly qualified professionals who are able to 
systematically carry out educational and training programs tailored to gender and age specific 
populations and to ensure that smokers gave up this bad habit.  
8. Intensive health education and anti-tobacco campaigns in media are effective ways to reduce 
smoking. It is very important to mobilize social movements against tobacco use and form a 
social climate conducive to reduce smoking. The public should have more information on 
structures, finance, database and political influence of tobacco industry. It is important that 
general public and especially children, youth and vulnerable groups are fully informed about 
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the medical and social consequences of tobacco smoking. Moreover, it is necessary to 
continue to closely work with social community and nongovernmental organizations to 
improve policies against smoking. 
It is important to note that tobacco smoking continues to be one of the major health challenges facing 
the European WHO region. Solutions to this problem are well known. However, for their successful 
implementation requires political support and mobilization of all social forces.  
6.4 European Policy against cancer 
The purpose of this sub chapter is to identify the main requirements for policies and strategies of 
cancer control, emphasizing the basic elements of primary prevention, secondary prevention 
(screening), comprehensive care and advances in research, all at the national and EU level. 
 After cardiovascular diseases, cancer still remains a major public health problem in the EU. In 
order to develop and implement of a successful plan for cancer control, early detection and quality 
care remains as a major issue for all EU countries. The fight against cancer is one of the basic and 
essential priorities of the European Association of Public Health since 1985. Three programs for 
action, entitled "Europe against Cancer" have been successfully implemented in the period from 1987 
to 2002. In April 2008, the European Parliament and European Council adopted a resolution cancer 
and the reduction of the cancer burden in the European Union (Boyle et al. 2003:1312). 
 The aim of national policies for cancer control is to improve the outcomes for patients and 
reduce cancer mortality. The EU has a big responsibility to improve public health and to ensure that 
all community policies and activities contribute to the protection of human health. The most important 
question is how to implement existing knowledge into effective strategies against cancer at the 
population level of the EU. To develop a comprehensive strategy for cancer control should be 
implemented four basic components: 
1. Primary prevention: implementing measures in the fields of health promotion, lifestyle 
intervention and diseases prevention to decrease the exposure of individuals to key risk 
factors – special emphasis on children, young adults and women. 
2. Secondary prevention: early detection of diseases, allows reducing premature mortality 
and improving quality of life of cancer patients. Organization of mass screening is the 
basic and the most effective priority for all EU countries. 
3. Integrated care: ensuring the best treatment for all cancer patients. This requires the 
development of well-trained and highly skilled workers in various fields. Improving the 
quality of life of cancer patients and their families, through support, rehabilitation and 
palliative care. 
4. Research on cancer is focused on finding new solutions for all aspects of cancer, by 
identifying new opportunities for prevention, early detection, diagnosis and treatment. 
This can be achieved by funding and supporting research on all levels - EU, national, and 
through a network of institutions.  
The solution of the problems associated with oncological diseases at the national and international 
levels is vital. The first step is a detailed analysis of the recent and current situations. Nationally, this 
analysis must provide information on geographical and temporal structure of cancer morbidity, 
Maxat Kulzhanbekov: Development of lung cancer mortality in the European Union from 1980 to 2006 44  
mortality and survival, for each of the most frequent types of cancer. After that, it is necessary to 
establish priority areas for cancer control. Priority should be given to the development of national 
plans for cancer or - if such a plan already exists – to the evaluations of their achievements. One of the 
most important problems in health policy is to maintain a share of total national expenditure on health 
allocated to cancer control. Oncological assistance can still be considered one of the most complicated 
works, so it may require significant financial resources. This applies both to a sufficient number of 
highly qualified specialists and the availability of equipment and materials - cancer drugs and 
sophisticated diagnostic and therapeutic equipment, all of which can be quite expensive. Moreover, 
European health policy must recognize the exceptional importance and effectiveness of integrated 
information systems for the monitoring of cancer. The main suppliers of such information are cancer 
registries. Population based survey derived from cancer registries remain as an important tool for 
evaluating various measures to reduce the cancer burden of European population. Cancer research 
remains the most important initiatives for the future development of cancer. Research enables 
informing people about many ways of fighting against this terrible disease (e.g. the prevention, 
diagnosis and treatment of cancer). Researchers will bring new knowledge, ideas and solutions. In 
addition, an effective implementation of strategies in the fight against cancer can be achieved through 
increased public awareness of the harmfulness of such habits as a sedentary lifestyle, poor diet, 
obesity, alcohol, and smoking respectively (Albreht et al. 2008:1452) 
 It is important to emphasize that adequate cancer control requires a structured and coordinated 
approach at all levels of European society, (as international and regional levels), involving all 
interested parties (medics, demographers, politicians) , including cancer patients. Taking into account 
such factors as the vulnerability of older persons to cancer and continuing trends of aging of European 
population, we must continue to struggle against numerous factors contributing to the emergence of 
oncological diseases. Based on prevention, detection, and cost efficient care we can achieve optimal 
and favorable results. Well-designed, effective national cancer control programs are essential to 
















Chapter 7  
Mortality patterns 
7.1 Mortality trends by the most important causes of death 
Subchapter 6.1 describes mortality trends by the most important causes of death among males and 
females in the European Union countries. The primary aim of this part is focused on the discovery of 
mortality development from circulatory system diseases, malignant neoplasms and other causes of 
death. It is important to note that over the past century mortality and its causes had substantially 
changed in Europe and around the world. Numerous infectious diseases such as plague, cholera, 
tuberculosis were a serious threat to the lives of many European citizens. But all of these diseases 
have been left behind as well as significantly minimized due to a significant progress of medicine that 
successfully fights with them. From the second half of the 20th century in many European countries 
there have been quite significant changes in the structure of mortality. The high speed of 
industrialization of society and state, requiring high moral and physical resources could significantly 
affect the health of the European population. It is important to note that behavioral factors and health 
problems are closely interconnected, that is why such social phenomena as alcoholism, smoking, 
stress, poor diet and the lack of physical activity may directly affect the morbidity and mortality in 
many European countries. All these factors have played a crucial role. Society faced with chronic 
diseases of the circulatory system and cancer, which have become increasingly dominate. Currently, 
cardiovascular disease and neoplasms remains the most frequent and leading causes in both genders in 
the European Union countries. 
  According to obtained results, we can say that most of the Western European countries (e.g. 
France and Spain) had already achieved favorable decline of mortality caused by circulatory system 
diseases. In contrast to Western Europe, mortality development from cardiovascular disease and 
cancer is quite different in Eastern Europe. In transition period, many post-communist countries were 
behind of those crucial transformations, which Western countries had already gone. In particular, we 
can distinguish countries such as Latvia, Lithuania and Estonia, which experienced a collapse of the 
totalitarian regime, economic reforms from socialism to capitalism accompanied by numerous social 
problems that in turn could adversely affect the health of citizens. 
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Tab 3: Mortality caused by circulatory system diseases in selected years, EU countries, males, 
standardized death rates  (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 638.1 492.9 278.2 77.2 44 56
Belgium* 525.4 364.4 257.5 69.4 49 71
Bulgaria 715.8 813.0 821.8 113.6 115 101
Czech Republic 819.1 834.2 477.8 101.8 58 57
Denmark 555.0 472.8 243.8 85.2 44 52
Estonia* 984.3 926.6 688.8 94.1 70 74
Finland 696.2 563.3 317.2 80.9 46 56
France 381.8 267.3 174.3 70.0 46 65
Germany* … 510.4 292.3 … … 57
Greece 403.4 415.7 310.1 103.1 77 75
Hungary 843.3 806.3 590.7 95.6 70 73
Ireland 705.1 547.2 265.5 77.6 38 49
Italy 516.7 374.4 225.4 72.5 44 60
Latvia 940.5 878.8 779.2 93.4 83 89
Lithuania* 677.0 738.5 740.6 109.1 109 100
Netherlands 473.5 391.0 222.1 82.6 47 57
Poland 737.9 768.1 480.2 104.1 65 63
Portugal* 567.1 466.9 271.1 82.3 48 58
Romania 825.7 775.2 726.9 93.9 88 94
Slovakia 742.6 774.0 634.9 104.2 85 82
Slovenia 663.0 557.4 322.0 84.1 49 58
Spain 445.1 337.1 208.7 75.7 47 62
Sweden 568.2 446.0 261.9 78.5 46 59
United Kingdom 619.9 474.8 246.2 76.6 40 52
Countries Circulatory diseases Index (%)
Males
 
 Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004 
  Source: Author’s own calculation based on data from WHO mortality database 
Table 3 illustrates that mortality development from circulatory system diseases among males in the 
European Union countries was quite heterogeneous. From the beginning of 1980 a large number of 
deaths from cardiovascular disease were observed in most of the former socialist countries, but at the 
end of 1990 negative trends changed in a positive direction. From 1980 to 1990 mortality of the male 
population was significantly high in Lithuania, Latvia, Poland, Bulgaria, Greece, Slovakia and the 
Czech Republic, while in Belgium, Spain and the United Kingdom mortality rates were among the 
lowest. Index of mortality change shows that in subsequent years (1990-2006), mortality from 
circulatory system diseases among males was gradually deacreasing. The most favorable decline was 
observed in Ireland, Austria, Denmark, Finland, Germany, Slovenia and the United Kingdom. The 
highest death rates from circulatory system diseases of the male population were registered in 
Belgium and Lithuania. It can be noted that by the end of the 20th century most of the countries of the 
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European Union have made significant progress in reducing mortality from the circulatory system 
diseases.  
Tab 4: Mortality caused by malignant neoplasms in selected years, EU countries, males, standardized 
death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 288.8 271.9 212.3 94.2 74 78
Belgium* 324.3 307.6 235.3 94.8 73 77
Bulgaria 173.3 196.8 224.5 113.5 129 114
Czech Republic 336.2 358.7 284.2 106.7 85 79
Denmark 277.4 278.7 245.5 100.5 89 88
Estonia* 270.3 286.1 302.1 105.9 112 106
Finland 273.5 237.7 183.9 86.9 67 77
France 306.8 305.0 242.6 99.4 79 80
Germany* … 275.6 210.9 … … 77
Greece 205.1 215.5 207.4 105.1 101 96
Hungary 317.3 372.9 330.9 117.5 104 89
Ireland 253.7 269.7 218.7 106.3 86 81
Italy 274.0 291.3 223.5 106.3 82 77
Latvia 247.5 288.1 299.4 116.4 121 104
Lithuania* 244.3 283.0 299.5 115.9 123 106
Netherlands 311.7 301.2 234.6 96.6 75 78
Poland 265.1 299.5 293.6 113.0 111 98
Portugal* 212.2 217.1 216.2 102.3 102 100
Romania 191.8 190.0 240.8 99.1 126 127
Slovakia 265.7 314.0 301.5 118.2 113 96
Slovenia 300.5 294.6 277.4 98.0 92 94
Spain 222.3 261.1 232.8 117.4 105 89
Sweden 197.9 199.5 178.3 100.8 90 89





 Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004 
 Source: Author’s own calculation based on data from WHO mortality database 
According to table 4, it can be seen that mortality development from neoplasm was homogeneous 
across the European Union countries. From 1980 to 1990 mortality from cancer was significantly 
similar in many countries. The highest death rates were recorded in Latvia, Lithuania, Estonia, 
Hungary and the Czech Republic. Mortality rate of the male population was the lowest in Finland, 
Austria, Belgium, Romania and the Netherlands. Mortality rate from neoplasms was gradually 
deacreasing in the period from 1990 to 2006. In comparison with previous years cancer mortality was 
changed in a positive direction in most of the European Union countries. Thus, mortality substantially 
reduced in the countries like Austria, Belgium, Denmark, Germany, Ireland, the Netherlands, the 
Czech Republic and the United Kingdom. In the countries such as Hungary, Romania, Bulgaria, 
Portugal and the Baltic States mortality development of the male population remained high and 
unfavorable.  
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Tab 5: Mortality caused by other causes of deaths in selected years, EU countries, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 434.8 315.29 257.5 72.5 59 82
Belgium 471.9 399.0 336.6 84.5 71 84
Bulgaria 567.0 427.4 307.0 75.4 54 72
Czech Republic 443.3 410.8 269.4 92.7 61 66
Denmark 448.1 391.2 341.5 87.3 76 87
Estonia* 560.9 486.1 472.9 86.7 84 97
Finland 455.8 395.1 315.9 86.7 69 80
France 490.5 385.0 302.8 78.5 62 79
Germany* … 346.3 244.7 … … 71
Greece 411.4 266.4 214.1 64.7 52 80
Hungary 607.0 531.7 409.1 87.6 67 77
Ireland 456.5 401.5 269.7 88.0 59 67
Italy 413.6 315.2 223.1 76.2 54 71
Latvia 540.3 545.17 539.3 100.9 100 99
Lithuania* 583.6 445.25 555.2 76.3 95 125
Netherlands 313.1 325.4 284.9 103.9 91 88
Poland 723.0 518.7 394.3 71.7 55 76
Portugal* 786.0 522.7 387.4 66.5 49 74
Romania 466.9 428.5 324.3 91.8 69 76
Slovakia* … 454.6 350.5 … … 77
Slovenia* 513.8 442.6 327.6 86.1 64 74
Spain 422.6 375.69 314.1 88.9 74 84
Sweden 310.2 272.0 228.9 87.7 74 84





Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004, Slovakia 1992,  
Slovenia   1985 
Source: Author’s own calculation based on data from WHO mortality database 
Table 5 shows that in comparison with the circulatory system diseases, mortality development by 
other causes of death was substantially similar to the most of the Euopean Union countries. Initially 
(1980), male mortality was significantly high in Latvia, the Netherlands, Ireland, Spain and Sweden. 
Mortality rates were the lowest in Italy, Spain, Sweden, Greece and the United Kingdom. In 
subsequent years mortality rates from other causes of death remained substantially homogeneous in 
almost all countries of the European Union. The high mortality rate of the male population was typical 
to Lithuania, Latvia and Estonia.  
 Table 6 shows mortality differences from all causes of death among men. In the period from 
1980 to 2006 high mortality levels of the male population were observed in Bulgaria, Hungary, 
Poland, the Netherlands, the Czech Republic and the Baltic States. 
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Tab 6: Mortality caused by all causes of deaths in selected years, EU countries, males, standardized 
death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 1361.7 1080.06 748.0 79.3 55 69
Belgium 1321.6 1070.92 829.5 81.0 63 77
Bulgaria 1456.2 1437.09 1353.2 98.7 93 94
Czech Republic 1645.5 1606.43 1031.5 97.6 63 64
Denmark 1260.1 1118.31 830.8 88.7 66 74
Estonia* 1815.5 1698.86 1463.7 93.6 81 86
Finland 1405.1 1201.30 817.1 85.5 58 68
France 1179.2 957.27 719.7 81.2 61 75
Germany* … 1132.3 747.9 … … 66
Greece 1019.9 897.55 731.7 88.0 72 82
Hungary 1767.6 1710.9 1383.9 96.8 78 81
Ireland 1415.2 1218.5 756.9 86.1 53 62
Italy 1204.3 980.8 672.0 81.4 56 69
Latvia 1728.2 1712.10 1617.8 99.1 94 94
Lithuania* 1504.8 1466.72 1595.3 97.5 106 109
Netherlands 1098.3 1017.51 741.6 92.6 68 73
Poland 1725.9 1586.28 1168.2 91.9 68 74
Portugal* 1565.3 1210.66 874.7 77.3 56 72
Romania 1484.5 1393.65 1292.1 93.9 87 93
Slovakia* … 1430.8 1286.9 … … 90
Slovenia* 1477.3 1294.52 927.0 87.6 63 72
Spain 1090.1 973.86 755.5 89.3 69 78
Sweden 1076.4 922.37 669.1 85.7 62 73
United Kingdom 1321.0 1057.34 732.7 80.0 55 69
All causes Index (%)Countries
Males
 
Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004, Slovakia 1992, Slovenia   1985 
Source: Author’s own calculation based on data from WHO mortality database 
From 1990 and 2006 mortality rates from all causes of death remained extraordinary high in the Baltic 
States, while the most favorable reduction was observed in countries such as Austria, Ireland, Italy, 
the Czech Republic, Finland and the United Kingdom.  
As it was mentioned above, over the past few decades most of the European Union countries 
have made significant progress in reducing mortality rate of the male population caused by the 
circulatory system diseases and cancer. The favorable trends in many Western European countries 
resulted in implementing effective measures for their own recovery. Substantial changes in behavior 
such as tobacco smoking cessation, absistence from alcohol, eutrophy and physical activity will 
reduce the risk of the leading death causes like cancer and cardiovascular diseases. 
 
 
Maxat Kulzhanbekov: Development of lung cancer mortality in the European Union from 1980 to 2006 50  
Fig. 5– Mortality caused by neoplasms and circulatory diseases, EU countries, 1980, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Estonia 1981, Lithuania 1981, Slovenia 1985, 
 Source: Author’s own calculation based on data from WHO mortality database  
 Fig. 6 - Mortality caused by neoplasms and circulatory diseases, EU countries, 1990, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Slovakia 1992  
 Source: Author’s own calculation based on data from WHO mortality database   
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Fig. 7 - Mortality caused by neoplasms and circulatory diseases, EU countries, 2006, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Belgium 2004, Portugal 2003, Slovakia 2005, 
 Source: Author’s own calculation based on data from WHO mortality database 
Comparative analysis allows to reveal mortality development from malignant neoplasms, circulatory 
diseases and other causes of death.  According to Figure 1 it can be highlighted that mortality 
development caused by circulatory system diseases in 1980th was very intense in most of the Eastern 
European countries (Estonia, Latvia, Hungary, the Czech Republic and Romania). The highest level 
was recorded in Estonia (984 deaths per 100 000 men). In comparison with Eastern Europe, mortality 
rates among Western countries (for example: the United Kingdom, Belgium, Denmark, France, Spain, 
Sweden and Greece) were significantly low.  According to Figures 2 and 3 it can be seen that 
mortality development of the male population was gradually declining in most of the West European 
countries. In 1990s mortality rate from the circulatory system diseases was the lowest in France (267 
deaths per 100 000 men), while in the Czech Republic it was one of the highest (926 deaths per 100 
000 men). The most favorable death rates caused by neoplasms were recorded among Swedish men 
(204 deaths per 100 000 persons). Extremely high rate was observed in Hungary (372 deaths per 100 
000 men). Mortality development from other causes of deaths was most common among the former 
socialist European countries, particular in Latvia (542 deaths per 100 000 men).The lowest death rates 
were recorded in Greece and Sweden (266-272 deaths per 100 000 men). In the later period of the 
study (2006) mortality from circulatory diseases patterns for the male population considered to be 
extraordinary high in Bulgaria (821 deaths per 100 000 men) and the lowest were observed in France 
(174 deaths per 100 000 men). Mortality rate caused by neoplasms remained high in Hungary (337 
deaths per 100 000 men), while it was the lowest in Sweden (178 deaths per 100 000 men). Mortality 
patterns from other causes of deaths continued to be high in the Baltic States (539-555 deaths per 100 
000 men). The lowest death rate was recorded among Greek males (214 deaths per 100 000 men). 
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Tab 7: Mortality caused by circulatory system diseases in selected years, EU countries, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 434.2 321.4 192.5 74 44 60
Belgium* 330.7 227.4 168.7 69 51 74
Bulgaria 567.7 586.4 540.8 103 95 92
Czech Republic 549.2 512.6 318.2 93 58 62
Denmark 315.9 280.3 154.4 89 49 55
Estonia* 611.3 557.8 360.3 91 59 65
Finland 383.3 311.8 171.3 81 45 55
France 230.4 159.3 102.1 69 44 64
Germany* 326.9 201.8 … … 62
Greece 327.0 329.9 259.3 101 79 79
Hungary 574.0 524.5 401.4 91 70 77
Ireland 451.7 318.6 159.6 71 35 50
Italy 354.4 249.5 151.0 70 43 61
Latvia 608.6 543.2 421.1 89 69 78
Lithuania* 492.1 483.4 439.8 98 89 91
Netherlands 618.3 217.1 138.6 35 22 64
Poland 463.8 462.2 291.9 100 63 63
Portugal* 418.5 337.7 194.1 81 46 57
Romania 719.3 645.1 531.0 90 74 82
Slovakia 518.6 479.3 417.5 92 81 87
Slovenia 444.1 371.4 212.5 84 48 57
Spain 325.7 246.1 139.7 76 43 57
Sweden 323.8 255.8 162.9 79 50 64
United Kingdom 366.9 281.4 155.9 77 42 55
Countries Circulatory diseases Index (%)
Females
 
Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004 
Source: Author’s own calculation based on data from WHO mortality database 
Table 7 revelas that mortality patterns of the female population caused by circulatory system diseases 
were substantially homogeneous among most of the European Union countries. According to the 
index of mortality change, between 1980 and 1990, the highest death rate was recorded in Bulgaria, 
Greece and Poland. The lowest mortality rate was observed in the Netherlands. In addition, the 
favorable mortality patterns prevailed among French, Spanish, Belgian, Irish and Italian women. It is 
important to note that from 1990 to 2006 mortality rates from the circulatory system diseases were 
gradually declining in the European Union countries. Despite of this, the countries with sufficiently 
low and high rates of women’s mortality can be distinguished. In such countries as Bulgaria, 
Romania, Hungary, Latvia, Lithuania, Slovakia female mortality rates were among the highest. 
Significant reduction of mortality patterns from the circulatorty system diseases was recorded in 
Austria, Belgium, Denmark, Finland, Ireland, Spain, the Netherlands, and the United Kingdom.  
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Tab 8: Mortality caused by malignant neoplasms in selected years, EU countries, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 176.4 164.4 127.5 93 72 78
Belgium* 169.8 155.4 130.8 92 77 84
Bulgaria 111.8 117.1 124.2 105 111 106
Czech Republic 180.9 191.8 163.2 106 90 85
Denmark 188.0 201.4 182.1 107 97 90
Estonia* 139.2 143.7 143.4 103 103 100
Finland 140.8 136.9 113.4 97 81 83
France 142.7 133.6 112.2 94 79 84
Germany* … 165.0 131.9 … … 80
Greece 117.1 113.3 111.0 97 95 98
Hungary 191.7 197.3 172.7 103 90 88
Ireland 185.4 182.9 159.8 99 86 87
Italy 145.7 148.2 122.6 102 84 83
Latvia 134.6 142.3 145.5 106 108 102
Lithuania* 130.0 138.4 133.4 106 103 96
Netherlands 163.1 165.8 154.3 102 95 93
Poland 153.4 156.0 154.9 102 101 99
Portugal* 128.7 129.1 110.8 100 86 86
Romania 124.1 117.6 132.6 95 107 113
Slovakia 144.3 148.5 145.7 103 101 98
Slovenia 156.8 155.4 145.4 99 93 94
Spain 120.3 123.6 103.3 103 86 84
Sweden 159.6 144.2 135.3 90 85 94
United Kingdom 183.7 187.7 153.7 102 84 82




Notes: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004 
Source: Author’s own calculation based on data from WHO mortality database 
According to Table 8, it can be noticed that mortality development of the female population caused by 
neoplasms was quite similar among the European Union countries. The index of mortality change 
shows that significantly high indices were observed in Bulgaria, Czech Republic, Denmark, Hungary, 
Italy, the Netherlands, Poland, Portugal, Slovakia, United Kingdom and the Baltic States. In contrast 
to the above-mentioned countries significantly low rates were recorded in Belgium, Austria and 
Sweden. From 1990 to 2006 mortality patterns of the female population were changed in a favorable 
direction in most of the countries of the European Union (e.g. Germany, Belgium, Finland, France, 
Sapin, the Czech Republic and the United Kingdom), while in Bulgaria, Romania, Poland, Slovakia 
and the Baltic States mortality remained high. It can be concluded that substantial diversity among 
Western and some Eastern European countries still remained throughout the entire period. Mortality 
patterns of the female population continued to be characterised by high death rates in most of the 
former socialist European countries. 
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Tab 9: Mortality caused by other causes of deaths in selected  years, EU countries, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 211.3 157.7 139.7 75 66 89
Belgium 281.9 223.23 202.5 79 72 91
Bulgaria 331.2 227.0 150.1 69 45 66
Czech Republic 226.3 193.4 133.7 85 59 69
Denmark 225.4 234.3 231.6 104 103 99
Estonia* 190.1 183.8 165.7 97 87 90
Finland 213.9 198.1 162.8 93 76 82
France 251.9 203.5 162.9 81 65 80
Germany* 181.4 143.5 … … 79
Greece 291.5 175.73 147.7 60 51 84
Hungary 295.3 245.40 183.6 83 62 75
Ireland 281.7 237.0 185.5 84 66 78
Italy 216.3 170.8 129.2 79 60 76
Latvia 181.6 213.7 220.5 118 121 103
Lithuania* 198.6 163.8 176.1 82 89 108
Netherlands 185.3 193.2 203.1 104 110 105
Poland 321.7 233.59 164.7 73 51 70
Portugal* 403.5 268.8 210.3 67 52 78
Romania 270.2 211.3 144.8 78 54 69
Slovakia* … 212.0 151.0 … … 71
Slovenia* 221.2 188.9 146.0 85 66 77
Spain 223.0 191.7 177.8 86 80 93
Sweden 178.4 159.4 154.6 89 87 97





 Note: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004, Slovakia 1992,  
 Slovenia   1985 
 Source: Author’s own calculation based on data from WHO mortality database 
Table 9 shows that female mortality rates from other causes of death significantly varied among the 
countries of the European Union. According to the index of mortality changes, from 1980 to 1990, 
mortality patterns of the female population were recorded high in Latvia, Lithuania, Denmark and the 
Netherlands, while in Greece and Italy it was the lowest. In the period from 1990 to 2006 mortality 
rates among females were gradually declining in most of the European Union countries. The most 
favorable patterns were found in Bulgaria, Romania, the Czech Republic and Poland, while in Latvia, 
Lithuania, Denmark, the Netherlands and the United Kingdom women's mortality rate remained 
extremely high. It is important to note that throughout the entire period mortality development from 
other causes of deaths significantly decreased among many countries. Despite this fact, there are 
several countries such as Latvia, Denmark and the Netherlands, where mortality indices of the 
females continued to be very high. 
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Tab 10: Mortality caused by all causes of deaths in selected years, EU countries, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
1980 1990 2006 1990/1980 2006/1980 2006/1990
Austria 821.9 643.40 459.7 78 56 71
Belgium 782.4 606.07 501.9 77 64 83
Bulgaria 1010.7 740.53 815.1 73 81 110
Czech Republic 966.4 897.7 615.0 93 64 69
Denmark 729.3 702.51 568.1 96 78 81
Estonia* 940.6 885.29 669.4 94 71 76
Finland 724.5 651.2 447.5 90 62 69
France 624.9 496.35 377.2 79 60 76
Germany* … 673.3 477.2 … … 71
Greece 735.6 618.89 518.0 84 70 84
Hungary 1061.1 967.22 757.7 91 71 78
Ireland 918.8 738.5 504.9 80 55 68
Italy 716.5 568.43 402.8 79 56 71
Latvia 924.8 899.14 787.2 97 85 88
Lithuania* 820.7 785.6 749.4 96 91 95
Netherlands 618.3 576.1 496.0 93 80 86
Poland 939.0 851.77 611.5 91 65 72
Portugal* 950.7 735.7 515.2 77 54 70
Romania 1113.6 974.0 808.3 87 73 83
Slovakia* … 780.5 714.1 … … 92
Slovenia* 822.0 715.80 503.9 87 61 70
Spain 669.0 561.4 420.9 84 63 75
Sweden 647.3 563.4 452.7 87 70 80
United Kingdom 789.8 662.5 510.5 84 65 77
Countries
Females
All causes Index (%)
 
Note: Belgium 2004, Germany from 1990, Estonia 1981, Lithuania 1981, Portugal 2004, Slovakia 1992,  
Slovenia   1985 
Source: Author’s own calculation based on data from WHO mortality database 
Table 10 illustrates mortality development of the female population caused by all causes of deaths. 
From 1980 to 1990 the mortality patterns among females were recorded as high in Denmark, Finland, 
the Netherlands, Hungary, Poland, the Czech Republic and the Baltic States, while in Austria, 
Belgium, Bulgaria, Italy, France and Portugal these patterns were considered low. In the period from 
1990 to 2006 mortality increased in Bulgaria, Slovakia and remained high in Lithuania. In all other 
countries of the European Union mortality patterns from all causes of deaths changed in positive 
direction. It is important to note that throughout the entire period mortality development of the female 
population was gradually declining. It can be said that a significant and beneficial reduction in 
mortality among women in the European Union could be related to improving lives and health of the 
citizens, i.e. high level of social stability and the progress in medicine, which play an important role in 
people's lives. 
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Fig. 8- Mortality caused by neoplasms and circulatory diseases, EU countries, 1980, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Estonia 1981, Lithuania 1981, Slovenia 1985,  
 Source: Author’s own calculation based on data from WHO mortality database   
Fig. 9- Mortality caused by neoplasms and circulatory diseases, EU countries, 1990, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Slovakia 1992  
 Source: Author’s own calculation based on data from WHO mortality database   
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Fig. 10- Mortality caused by neoplasms and circulatory diseases, EU countries, 2006, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Belgium 2004, Portugal 2003, Slovakia 2005 
 Source: Author’s own calculation based on data from WHO mortality database 
According to Figure 8, it can be concluded that mortality development of the female population 
caused by the circulatory system diseases was the highest in Romania (719 deaths per 100 000 
women). Also, mortality patterns were significantly high in Bulgaria, Hungary, the Czech Republic, 
Slovakia and the Baltic States. The lowest death rate was recorded among French women (230 deaths 
per 100 000 women). In comparison with the circulatory system diseases, development of cancer 
mortality was similar in most of the European Union countries. The highest death rate was in Hungary 
(191 deaths per 100 000 women), while the lowest was observed in Greece. Mortality development 
from other causes of death was significantly different between Western and post-communist Europe. 
It is important to note that mortality patterns were extraordinary high (403 deaths per 100 000 
women) among Portuguese women. The lowest death rate was observed in Sweden (178 deaths per 
100 000 women). Figure 9 reveals that most of the European women were suffering from the 
circulatory system diseases. Mortality level was extremely high in Romania (719 deaths per 100.000 
women) as well in Bulgaria, Slovakia, the Czech Republic, Hungary and the Baltic States. The lowest 
death rate was recorded in France (230 deaths per 100.000 women). Mortality development from 
neoplasms was considered as high among Hungarian and Czech women (191-197 deaths per 100 000 
women), the lowest was observed in Greece (113 deaths per 100 000 women). In regards to other 
causes of deaths mortality patterns were homogeneous among the European Union countries.  
 Figure 10 shows that mortality development from the circulatory system diseases, malignant 
neoplasms and other causes of deaths was gradually declining in most of the Western European 
countries (e.g. France, Belgium, Italy, Spain, Sweden and the the Netherlands), while mortality 
patterns remained extremely high among the former socialist European countries  (e.g. Bulgaria, 
Romania, Hungary, Slovakia and the Baltic States). 
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7.2 Malignant neoplasms within mortality development  
The epidemiological transformation that took place after the Second World War in Europe was 
delayed in the Eastern European countries compared to countries of Northern and Western Europe.  
However, as death rates from cardiovascular disease have begun to fall since the 1990s, malignant 
neoplasms has emerged as the most common cause of death among young and middle-aged adult 
women (20-64 years old) in the Central and Eastern European countries. It seems likely to be the 
leading cause of death among young and middle-aged adult men (Zatonski and Didkowsa 2008:1425). 
 Europe comprises only one-eighth of the total world's population, but despite this, one quarter 
of the global total cancer cases – some 3.2 million new patients each year are observed in Europe (F, 
Bray, 2008:7). It is important to note that mortality development from neoplasms in Europe is still 
determined by the vector of West and East (post-communistic). Mortality differentiation among 
frormer socialist countries of Europe is very considerable and continues to be quite problematic. We 
can say that most of the post communist countries (for example: Baltic States) by the end of the 80's 
to mid 90's underwent major problems, which in turn could negatively affect the demographic 
situation.     
 It is important to know that there are many factors contributing to the emergence of cancer. For 
example high blood pressure and high cholesterol are closely linked to excessive consumption of 
fatty, sugary and salty foods. The impact of these factors becomes even more lethal when combined 
with the deadly consequences of smoking and excessive alcohol consumption, which cause various 
types of cancer and cardiovascular disease, stroke and other serious illnesses (Demoscope, 2002).  
 In the 20th century mortality development from neoplasms was typically high among males. 
But, over the past few decades mortality is gradually declining, while among the female population 
mortality patterns caused by cancer started to speedy increase. There are many different hypotheses 
about the causes of increased mortality among women in industrialized countries. One of the most 
credible reasons is the emancipation of women. We can assume that over the last fifty years years in 
many industrialized countries, level of equality between men and women is becoming increasingly 
evident. We believe that gender equality has led to massive changes in the behavior of women. For 
example numerous kinds of job in the recent past had been occupied exclusively by men. Currently 
they are being developed by women. We can not exclude that these factors influence the behavior of 
women, which can have a negative impact on mortality structure among women. 
 In order to understand which factors shape a given level of mortality we need to know how 
people's health changes and how this change affects on their life. Nowadays, the society can be 
divided into two camps, the first of them – the number of people who know and understand all kinds 
of negative phenomena (drinking alcohol, drug addiction and cigarette consumption) but nevertheless 
continue to be exposed to these influences, the second - this is a relatively smaller number of people, 
but who are seriously concerned and taking over all efforts to maintain and improve their health. To 
protect people live the European Union countries must activate the following public reactions: 
      -  Requirement to tighten protection of the environment; 
- Strengthen the individual health prevention  
- Promotion of healthy lifestyles. 
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Fig. 11- Mortality caused by malignant neoplasms, Western European countries, 1980-2006, males, 
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Fig. 12-Mortality caused by malignant neoplasm, post-communist European countries, 1980-2006, males, 
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 Fig. 13- Mortality caused by malignant neoplasms, Western European countries, 1980-2006, females, 
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Fig. 14- Mortality caused by malignant neoplasm, post-communist European countries, 1980-2006, 
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According to Figure 11 it can be noted that mortality development from neoplasms was the most 
common among Western European countries. Extremely high mortality rate was observed in 
Belgium, the Netherlands, France, United Kingdom, Italy, Denmark and Austria. One of the most 
striking examples is the Netherlands. From 1980 to 2006 mortality significanlty decreased (311 to 234 
deaths per 100 000 men) among Dutch males. Mortality from neoplasms was significantly low in 
Finland, Greece and Portugal. One of the lowest death rates was recorded in Sweden (182-178 deaths 
per 100 000 men). 
 Figure 12 illustrates mortality trends of the male population in post-communist European 
countries. Throughout the entire period mortality development from neoplasms was the highest in 
Hungary (401 deaths per 100 000 men). Moreover, mortality was significantly high among the Czech 
and Slovakian males. It can be seen that mortality among the male population was very intense in 
Slovenia and the Baltic States. The lowest death rates of the males were recorded in Bulgaria and 
Romania. In contrast to West European countries where the death rates of the male population were 
gradually declining, post communist countries faced an intensive growth. 
Figure 13 shows that mortality development among females was significantly heterogeneous in 
West Eropean countries. Extremely high level of deaths was recorded in 1995 among Danish women 
(209 deaths per 100 000 women). Also, mortality rates from neoplasms were significantly high in 
Ireland and the United Kingdom. One of the most sound example is Greece where mortality was less 
than 120 deaths per 100 000 women throughout the entire period. In addition, mortality patterns were 
considered low in Spain and Portugal. It is important to note that from 1980 to 2006 mortality 
development of the female population significantly changed. It was gradually declining in almost all 
the European Union countries. 
The results obtained from Figure 14 show that mortality patterns of women were very 
different across the post communist European countries. Three distinct trends can be observed. 
Firstly, Hungary and the Czech Republic have to be defined. Mortality development from neoplasms 
in these countries was extremely high in contrast to other countries. One of the most critical levels of 
mortality was recorded in Hungary during the period from 1992 to 1999 (205 deaths per 100.000 
women). Secondly, development of cancer mortality which was observed in Slovenia, Slovakia, 
Latvia, Lithuania and Estonia was comparatively higher than in Romania and Bulgaria but less than 
in Hungary. The highest fluctuation was recorded in 1992 among Slovenian women (168 deaths per 
100 000 women). The third group of countries includes Romania and Bulgaria. From 1981 and 1993 
mortality patterns of the female population was quite similar in both countries. Substantial differences 
were observed from 1995, death rates in Bulgaria started to increase, while in Romania it changed in 
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Fig. 15-Index of mortality changes caused by malignant neoplasms, Western European countries, 1980-
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Fig. 16-Index of mortality changes caused by malignant neoplasms, post-communist European countries, 
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According to Figure 15, it can be noted that mortality development from neoplasm for both sexes was 
very intense in France and Spain. Mortality patterns in Belgium, Greece and Italy were comparatively 
lower than in France, but higher than in other Western European countries. The most striiking 
example was recorded in Denmark, Ireland, Sweden and the United Kingdom. Mortality from 
malignant neoplams was gradually reducing in all the countries except France and Spain. The most 
significant reduction was recorded among Dutch and Finnish people. 
 Figure 16 shows that mortality patterns seemed to be homogeneous in most of the post-
communist European countries. Mortality from cancer was intensively high in the Baltic States. Also, 
significantly high indeces of male and female mortality were found in such countries as Slovakia, 
Hungary and Poland. Mortality patterns among Czech people were significantly intense in 1990s, but 
in the later study period a favourable reduction can be observed. The development of cancer mortality 
in Bulgaria was recorded significantly low. 
 Based on the above analysis, substantial differences among West and East European countries 
can be revealed. In most of the West European countries cancer mortality is still declining, while in 
the former socialist countries mortality continued to be much more intense and less favorable.  
7.3. Mortality from the most frequent malignant neoplasms  
This part aimed to identify comprehensive information about mortality development from the most 
frequent neoplasms. Malignant neoplasms are still major and dramatically increasing causes of death 
throughout the European Union countries. There are significant differences in mortality trends among 
the West and former socialist countries of Europe. These can be partially explained by differences in 
cancer risk factors, lifestyle-related and environmental, including tobacco smoking, alcohol, dietary 
habits and pollution. Moreover, many differences have their roots in social and economic inequalities 
as a consequence of political systems and reforms that existed among various geopolitical regions in 
Europe. It is important to note that political and economic transformation in former communist 
countries of Central and Eastern Europe has been quite difficult for countries (mainly for the Baltic 
Statest), which greatly influenced the growth of morbidity and mortality from various forms of 
cancer. In addition, the time trends in cancer mortality also vary between European Union countries 
and some forms of neoplasms show different trends between men and women. For example, mortality 
patterns caused by lung cancer substantially reduced in many countries among men (particularly the 
more vulnerable groups) but increasing among women, particularly the young. In other countries, 
(e.g. Hungary) lung cancer rates are still increasing in both sexes. Mortality patterns varied for many 
other form of cancer. For instance breast cancer is the disease which most frequently diagnosed 
among the female population of the European Union.  
 Over the last century, the diagnosis of cancer is often associated as a death sentence, but 
substantial progress in medical knowledge allowed achieving significant results in the struggle for 
human’s life. In particular, innovations such as screening, surgery, radiation therapy and 
pharmaceuticals have made it possible to offer a higher probability of cure of cancer patients. 
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Tab 17: Mortality from the most frequent malignant neoplasm, EU countries, 1980, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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  Notes: the Czech Republic 1986, Estonia 1981, Lithuania 1981, Slovenia 1985  
  Source: Author’s own calculation based on data from WHO mortality database   
Tab 18: Mortality from the most frequent malignant neoplasm, EU countries, 1990, males, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Slovakia 1992  
 Source: Author’s own calculation based on data from WHO mortality database   
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Tab 19: Mortality from the most frequent malignant neoplasm, in European Union, 2006, 
males, standardized death rates (per 100 000 persons, WHO European Population Standard) 
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  Notes: Belgium 2004, Portugal 2003, Slovakia 2005 
  Source: Author’s own calculation based on data from WHO mortality database   
Figure 17 reveals that mortality patterns from lung cancer were the most common among other forms 
of malignant neoplasms in the European Union countries over the last two decades. In 1980 mortality 
development of the male population was the highest in the Czech Republic (115 deaths per 100 000 
men). Also, death rates were singnificantly high in Belgium, the Netherlands, Hungary and the United 
Kingdom. In contrast to the above-mentioned countries, the lowest mortality rate was recorded in 
1980 among Portuguese (30 deaths per 100 000 men). Mortality development caused by stomach 
cancer was the most frequent after the lung cancer. One of the highest death rate was recorded in 
Lithuania (51 deaths per 100 000 men). In addition, mortality rate was significantly high in Estonia, 
Latvia, Portugal and Poland. The lowest death rates were observed in Denmark, Spain, Sweden and 
Greece (17-19 deaths per 100 000 men). The third in the frequency of death among European men 
was colorectal cancer. Mortality rates in the Czech Republic were recorded as extremely high (51 
deaths per 100 000 men), while in Greece, mortality from colorectal cancer was very low (8 deaths 
per 100 000 men). Regarding prostate cancer, it can be noted that mortality patterns were substantially 
homogenous in many countries of the European Union. The highest death rates were among Swedish 
men (35 deaths per 100 000 men), while the lowest were in Bulgaria (10 deaths per 100 000 men). In 
contrast to the above-mentioned neoplasm causes, mortality development from bladder cancer was 
considered low and quite similar in most of the European Union countries.  
 According to Figure 18, it can be seen that mortality development from lung cancer was the 
highest among Hungarian and Czech males (112-113 deaths per 100 000 men). The lowest death rates 
were recorded in Sweden and Portugal (35-38 death per 100 000 men). Regarding mortality patterns 
from stomach cancer, it can be said that the highest deaths rates remained in Lithuania (43 deaths per 
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100 000 men), while the most favorable decline was observed in Bulgaria, Sweden, France and 
Greece (13-14 deaths per 100 000 men). Mortality development caused by colorectal cancer remained 
extraordinary high in the Czech Republic (53 deaths per 100 00 men), while it was the lowest among 
Greek males (10 deaths per 100 000 men). Mortality patterns of prostate cancer, which were 
considered low and homogeneous in 1980, substantially increased in most of the European Union 
countries during the 1990s. The highest death rate was still prevailing in Sweden (36 deaths per 100 
000 men). In contrast to the above-mentioned neoplasm causes, mortality development of bladder 
cancer was lower among the male population of the European Union countries.   
 Figure 19 shows that lung cancer mortality was significantly favorable among most of the 
Western European countries. It is important to note that death rates were considered low in such 
countries as Sweden and Finland (31-46 deaths per 100 000 men), while in most of the former 
communist countries it remained extraordinary high (e.g. Hungary, Poland and the Baltic States). 
Mortality development from stomach cancer which was high in 1980 and 1990s, substantially 
decreased in 2006.  Despite this fact,  it can be determined that mortality was high across the Baltic 
States (29-32 deaths per 100 000 men). It should be emphasized that mortality patterns from 
colorectal cancer significantly reduced in Western Europe than among former communist countries. 
Mortality was considered unfavorably high in the Czech Republic, Hungary and Slovakia (45-47 
deaths per 100 000 men).  
 Based on the above analysis, it can be concluded that lung cancer still remains one of the most 
dominant and the most frequent cause of death among the male population of the European Union 
countries. It has to be mentioned that the differentiation of male mortality between Western and 
Eastern (former communist) countries of the European Union is still a significant and problematic 
argument in cancer research. 
Tab 20: Mortality from the most frequent malignant neoplasm, EU countries, 1980, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: the Czech Republic 1986, Estonia 1981, Lithuania 1981, Slovenia 1985,  
 Source: Author’s own calculation based on data from WHO mortality database   
Tab 21: Mortality from the most frequent malignant neoplasm, EU countries, 1990, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Slovakia 1992  
 Source: Author’s own calculation based on data from WHO mortality database   
Tab 22: Mortality from the most frequent malignant neoplasm, EU countries, 2006, females, 
standardized death rates (per 100 000 persons, WHO European Population Standard) 
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 Notes: Belgium 2004, Portugal 2003, Slovakia 2005, 
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 Source: Author’s own calculation based on data from WHO mortality database   
According to Figure 20, development of breast cancer mortality in 1980 was the most frequent across 
Western European countries. Extremely high mortality rates were recorded in Belgium, the 
Netherlands, Denmark and the United Kingdom (36-40 deaths per 100 000 women). The lowest death 
rates were observed in Bulgaria, Romania, Latvia and Lithuania (16-18 deaths per 100 000 women). 
Mortality patterns from colorectal cancer were recorded at significantly high following the lung 
cancer. The highest mortality rate of the female population was typical for countries such as Denmark, 
the United Kingdom, Ireland, Hungary, the Czech Republic, Austria, Belgium and the Netherlands 
(23-30 deaths per 100 000 women). Regarding stomach cancer, mortality development was 
significantly high in Portugal and the Baltic States (22-24 deaths per 100 000 women), while among 
Greek and Danish women it was the lowest (9-10 deaths per 100 000 women). It is important to know 
that lung cancer mortality was differentiated across most of the European Union countries. Mortality 
rate was the highest in Denmark, Ireland and the United Kingdom (21-25 deaths per 100 000 women). 
In contrast to the above-mentioned neoplasm causes, mortality from bladder cancer was the lowest. 
 Figure 21 shows that in 1990 mortality from breast cancer cointinued to be extremely high 
Western Europe (e.g. Denmark, the United Kingdom, Ireland, the Netherlands and Belgium). In 
addition, mortality patterns significantly increased among the former communist countries (e.g. 
Bulgaria, Romania, Latvia and Lithuania). Mortality development from colorectal cancer among 
women remained quite homogeneous in many European Union countries. Despite this observations, it 
can be noted that the highest death rate was observed in Hungary (28 deaths per 100 000 women), 
while in Greece it was the lowest (8 deaths per 100 000 women). It is important to know that lung 
cancer mortality of the female population soared in contrast to previous years. The highest death rate 
was recorded in Denmark (38 deaths per 100 000 women), while it was the lowest among Spanish, 
French and Portuguese women (5-7 deaths per 100 00 women). Mortality patterns from stomach 
cancer remained homogeneous almost in all countries except Estonia and Latvia which remained at a 
high level. 
 Figure 22 illustrates significant differences in mortality development of the female population 
from the most frequent neoplasm causes. One of the most unfavorable changes in mortality patterns of 
women were observed in Denmark. The death rate from lung cancer in this country had been 
extraordinarily high (44 deaths per 100 000 women). The lowest death rate was observed in Portugal, 
Spain and Lithuania (8 deaths per 100 000 women). Although mortality from breast cancer was most 
frequently diagnosed in the European Union, mortality development of recent years indicates that 
lung cancer is becoming one of the most dominant types of malignant neoplasms among females. 
7.4. Lung cancer within mortality development 
Lung cancer has been a major public health problem in Europe for many years. This disease is the 
most frequent cause of death in males in the majority of the European Union countries and one of the 
most common in females. Tobacco smoking among people is still the main risk factor which 
contributes to the emergense of lung cancer. The aim of this subchapter is to analyze lung cancer 
mortality patterns and reveal the differences between West and former communist countries of 
Europe, with special emphasis on changes in temporal trends.  
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Fig. 23- Mortality caused by lung cancer, Western European countries, 1980-2006, males, standardized 
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Fig. 24 - Mortality caused by lung cancer, post-communist European countries, 1980-2006, males, 
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Fig. 25-Mortality caused by lung cancer, Western European countries, 1980-2006, females, standardized 












































































  Source: Author’s own calculation based on data from WHO mortality database   
 




Fig. 26- Mortality caused by lung cancer, post-communist European countries, 1980-2006, females, 











































































  Source: Author’s own calculation based on data from WHO mortality database   
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Figure 23 reveals that mortality patterns from lung cancer were significantly differentiat across 
Western European countries. From 1980 to 1986 mortality of the male population was extraordinary 
high in Belgium and the Netherlands (117-121 deaths per 100 000 men). Also, development of lung 
cancer mortality was significantly high in the United Kingdom and Finland (97-107 death per 100 000 
men), while the lowest death rate was recorded in Portugal and Sweden (less than 45 death per 100 
000 men). Throughout the entire period mortality patterns caused by lung cancer substantially 
deacreased in countries such as the Netherlands, the United Kingdom, Belgium and Finland. In 
general, since the second half of the 1980s, mortality patterns from lung cancer changed in many 
Western European countries, i.e. mortality was gradually deacreasing. 
 According to Figure 24 it can be said that development of lung cancer mortality among post 
communist European countries was significantly different. Throughout the entire period mortality 
from lung cancer was observed at an extremely high level in Hungary (121 deaths per 100 000 men). 
From 1980 to 1986 mortality rate was recorded as high in the Czech Republic (112-115 deaths per 
100.000 men), but in the subsequent years, it was rapidly declining. It is important to note, that one of 
the most intensive development of lung cancer mortality was observed in Slovenia, Slovakia, Poland 
and the Baltic States. In comparison with the above-mentioned countries, mortality patterns were 
considered low among Bulgarian and Romania females (62-66 deaths per 100 000 men). Since the 
mid 1990s lung cancer mortality of the male population changed in a favorable direction and was 
gradually declining almost in all the post-communist countries of Europe.  
 Chart 25 illustrates that lung cancer mortality of the female population in Western European 
countries was quite homogeneous. There are several countries (Denmark, the United Kingdom, 
Ireland, Netherlands and Sweden) where mortality can be considered high and intense. Development 
of lung cancer mortality among Danish women remains extremely high (for example from 1980 and 
2006 mortality level increased from 22 to 44 deaths per 100.000 women). It is important to note that 
development of lung cancer mortality was recorded high in the United Kingdom, Ireland and the 
Netherlands. One of the most sound example of mortality patterns from lung cancer was observed in 
Spain and Portugal (less than 10 deaths per 100 000 men). In contrast to mortality patterns of the male 
population, mortality from lung cancer among women remained unfavorable and steadily growing in 
most of the Western European countries (e.g. Denmark, the Netherlands and Sweden).  
 Figure 26 shows the over the past two decades lung cancer mortality rate was extraordinary 
high for Hungarian females. From 1980 to 2006 mortality among women increased from 15 to 31 
deaths per 100 000 women. In Poland, Slovenia and the Czech Republic women's mortality rate was 
relatively lower than in Hungary, but it showed a significant increase. In other post communist 
countries (Slovakia, Bulgaria, Romania and the Baltic States) development of lung cancer mortality 
was significantly low and homogeneous. One of the most striking example of mortality patterns was 
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Fig. 28- Index of mortality changes caused by lung cancer, post-communist European countries, 1980-
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According to the indeces of mortality change, most of the Western European countries show a 
different level of lung cancer mortality. Mortality patterns from lung cancer were recorded at an 
extremely high level in Spain throughout the entire period. Moreover, from 1980 to 1984 mortality 
development from lung cancer was very intensive in Belgium, France, the Netherlands and Finland. It 
is important to note that the increase of tobacco smoking as well as a various exogenous factors (e.g. 
air pollution, environmental contamination) could be the cause of high intensity in lung cancer 
mortality. It can be said that mortality from lung cancer in Western European countries had already 
passed its peak and is gradually declinig.          
 Among the post-communist European countries, mortality patterns from lung cancer can be 
considered high and very intense. The most unfavorable development was recorded in Lithuania. 
Moreover, lung cancer mortality fluctuated considerably in Slovakia and other Baltic States. 
Substantial progress in mortality reduction was observed in the Czech Republic. In contrast to 
Western Euope, mortality patterns due to lung cancer remained high and mostly unfavorable across 
former communist Europe. 
           It should be noted that the gender differences in lung cancer mortality continues to be quite a 
serious health problem in the European Union. Tobacco smoking as a major risk factor is a global 
threat against which people need to implement the most stringent and effective measures. Taking into 
account high and still growing incidence of lung cancer, the problem of prevention of the disease 
becomes extremely important for Europe.   
7.5 Age and sex distribution by lung cancer mortality 
In most of European countries considerable growth of lung cancer mortality among males and females 
occurred from the second half of the 20th century. At the end of 1990th lung cancer became the most 
extensive and frequently diagnosed form of oncological disease in the majority of European countries. 
Extremely high level of lung cancer mortality in European countries was caused by tobacco smoking 
habit. Tobacco smoking is affected by a whole variety of social, economic, cultural and behavioural 
determinants. Among many social changes which occurred in the 20th century in industrialized 
countries, smoking habits among women is the most visible. Smoking women can be considered one 
of the most pressing social and demographic challenges in the 21st century.  In spite of high consumer 
demand for tobacco products in Europe, the indicators of oncological pathology (lung cancer) in 
females are still lower than among men, but at the same time pernicious habits of young women 
(smoking) remains as the most serious problem. Everyone knows that carcinogenic substances contain 
in tobacco smoke adversely affects the lungs, which in turn contributes to lung cancer. Lung cancer is 
the first among men and the second most common malignant neoplasm after the breast cancer. It may 
be noted that lung cancer is the most common cause of death associated with tumors. Elderly people 
over 65 are the most numerous populations suffering from lung cancer (Batura-Gabryel, Foremska-
Iciek 2007). 
 The primary aim of this subchapter is to reveal what kind of age groups are the most vulnarable 
in terms of the lung cancer. We have separated males and females’ deaths on the following age-
groups: 0-44, 45-54, 55-64, 65-74, 75-84, 85+. This allows identifying which age group is the most 
affected in terms of lung cancer mortality.  
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Table.15a-f: Statistical variation by lung cancer mortality, for the period since 1980, 1990-2006, 
males-females in selected age-groups    
       
    a) Age-group: 0-44   b) Age-group: 45-54 
  
1980 1990 2006
EU 22 EU 24 EU 24
minimum 0.695 0.572 0.304
maximum 3.105 4.739 2.286
range 2.410 4.167 1.982
Average 1.865 1.868 0.953
St dev 0.68 0.93 0.51
Coef if var 36.3 49.6 53.8
minimum 0.139 0.219 0.148
maximum 2.284 2.652 1.794
range 2.145 2.433 1.646
Average 0.557 0.662 0.583
St dev 0.43 0.50 0.36
Coef if var 77.2 76.2 61.6
Male
Female
      
1980 1990 2006
EU 22 EU 24 EU 24
minimum 3.138 3.371 2.072
maximum 17.126 18.916 18.224
range 13.987 15.545 16.153
Average 9.400 9.738 7.259
St dev 3.34 4.15 3.68
Coef if var 35.5 42.6 50.7
minimum 0.701 0.530 0.942
maximum 6.601 8.388 7.276
range 5.900 7.858 6.334
Average 1.808 2.038 2.715
St dev 1.29 1.58 1.50




      Source: own calculation                                                         
According to the obtained results, it can be said that mortality patterns from lung cancer in the age 
group 0-44 were significantly different between males and females in the majority of the European 
Union countries. Mortality from lung cancer was the highest in the Czech Republic, while in Sweden 
it was considered low. For females, the maximum level remained high in Denmark and the lowest was 
observed in Latvia. In the age group 45-55, a significantly high level of male mortality from lung 
cancer was recorded in Hungary and the Czech Republic. Regarding women, the highest level of lung 
cancer mortality prevailed in Denmark and Hungary. 
   c) Age-group: 55-64   d) Age-groups: 65-74 
  
1980 1990 2006
EU 22 EU 24 EU 24
minimum 8.954 9.120 6.595
maximum 38.186 36.153 32.355
range 29.232 27.033 25.760
Average 22.029 23.754 18.234
St dev 7.27 8.05 6.46
Coef if var 33.0 33.9 35.4
minimum 1.215 1.083 1.789
maximum 8.503 14.991 11.201
range 7.288 13.908 9.412
Average 3.204 3.975 5.022
St dev 1.87 2.98 2.50
Coef if var 58.4 74.9 49.8
Male
Female
       
1980 1990 2006
EU 22 EU 24 EU 24
minimum 9.858 12.601 11.409
maximum 44.475 37.959 34.542
range 34.618 25.358 23.133
Average 26.082 27.002 22.817
St dev 9.52 7.53 6.56
Coef if var 36.5 27.9 28.7
minimum 1.575 1.453 1.856
maximum 8.315 11.753 15.663
range 6.740 10.301 13.806
Average 3.418 4.276 5.307
St dev 1.65 2.59 3.33




   Source: own calculation                           
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In the age-group 54-65 the maximum level of lung cancer mortality of the male population was 
recorded in Hungary and the Czech Republic, it was at the minimum level while in Sweden. Among 
females, mortality was considered extraordinary high in the United Kingdom, Denmark. The lowest 
indices of lung cancer mortality were recorded in Portugal and Spain.  
 In contrast to the above- mentioned age groups, lung cancer mortality in the age-group 65-74 
significantly increased for both sexes. The highest level of male mortality was observed in the 
Netherlands, Belgium and Poland, while it was considered low in Sweden and Portugal. Regarding 
female population, it can be noted that lung cancer mortality was the highest in Denmark and the 
United Kingdom. The lowest mortality index was recorded in France and Spain. 
  e) Age-group: 75-84       f) Age-group: 85+ 
  
1980 1990 2006
EU 22 EU 24 EU 24
minimum 4.472 4.040 6.416
maximum 26.90 27.004 18.779
range 22.423 22.963 12.363
Average 13.526 13.685 13.613
St dev 6.28 5.58 3.49
Coef if var 46.4 40.7 25.7
minimum 0.985 1.101 1.238
maximum 3.663 5.776 9.263
range 2.677 4.675 8.025
Average 1.760 2.209 3.289
St dev 0.67 1.18 2.07
Coef if var 38.1 53.2 63.0
Male
Female
           
1980 1990 2006
EU 22 EU 24 EU 24
minimum 0.481 0.235 1.210
maximum 6.746 8.151 6.823
range 6.265 7.916 5.613
Average 2.962 3.701 3.874
St dev 1.76 2.00 1.41
Coef if var 59.5 54.1 36.4
minimum 0.108 0.234 0.339
maximum 1.120 1.678 2.070
range 1.013 1.444 1.731
Average 0.587 0.701 1.028
St dev 0.29 0.32 0.46




  Source: own calculation                                                               
In comparison with the age-groups 54-64 and 65-74, lung cancer mortality of the male and female 
populations substantially decreased. Mortality level from lung cancer among males remained high in 
Belgium and the Netherlands. The lowest level was recorded in Romaina and Bulgaria. For females, 
mortality was considered high in Denmark, Ireland and the United Kingdom, while it was minimal in 
Portugal, Romania and Spain.  
 The favorable reduction of lung cancer mortality for both sexes was recorded for the last age- 
group (85+) in the majoriity of the European Union countries. But despite of this fact, the highest and 
the lowest indeces among them can be found. The maximim level of lung cancer mortality of the male 
population continued to be the highest in the Netherlands and the United Kingdom, while it was 
minimal in Romania and Bulgaria. Regarding women, mortality remained high in the United 
Kingdom, whereas in Estonia, Latvia and Bulgaria it was considered low.  
 From the analysis above, it can be conlcuded that lung cancer mortality for both sexes 
continued to be the highest in the age-groups 55-64, 65-74 and 75-84, that is why this form of 
neoplasm still remains the most common diagnosis among the elderly. Thus, it can be assumed that 
the probability of dying from lung cancer depends not only from tobacco smoking, but also from 
natural processes such as aging population, whose level is still increasing in many countries of the 
European Union. 
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 Fig. 29 - Mortality by age from lung cancer, EU countries, 1980, males 
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 Notes: the Czech Republic 1986, Estonia 1981, Lithuania 1981, Slovenia 1985  
 Source: Author’s own calculation based on data from WHO mortality database   
 Fig. 30 - Mortality by age from lung cancer, EU countries, 1990, males 
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  Fig. 31 -Mortality by age from lung cancer, EU countries, 2006, males 
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 Source: Author’s own calculation based on data from WHO mortality database   
According to the graphical indicators, mortality patterns from lung cancer were substantially different 
among older people. Figure 29 shows that lung cancer mortality in the age group 65-74 was the 
highest in comparison with the other age groups. The highest death rate was recorded in Belgium and 
the Netherlands (43-44 deaths per 100 000 men), while in the lowest was observed in Portugal. In the 
age group 55-64 the highest mortality rate was observed in the Czech Republic (38 deaths per 100 000 
men) and the lowest in Portugal and Sweden (8-9 deaths per 100 000 men). The age-group 75-84 was 
substantially different from above-mentioned age groups. The death rate was considered high in the 
Netherlands (26 deaths per 100 000 men), while it was minimal in Portugal (5 deaths per 100 000 
men). In contrast to previous age-groups, lung cancer mortality was considered low in the age groups 
0-44 and over 85 respectively. 
Figure 30 shows that lung cancer mortality still remained high in the age-group 65-74.  
Mortality was significantly high in the Netherlands (37 deaths per 100 000 men) and remained low in 
Portugal (13 deaths per 100 000 men). It is important to note that mortality from lung cancer was the 
most frequent in the age groups 65-74 and 55-64. The highest death rates were recorded in most of the 
former communist countries (Hungary, the Chech Republic, Poland, Slovenia, Slovakia and the Baltic 
States). Mortality among the age-group 75-84 was considered high in the Netherlands (27 deaths per 
100.000 men), while the lowest was found in Bulgaria (4 deaths per 100 000 men). Mortality patterns 
in the age groups 0-44, 45-54 and 85 remained low.  
To conclude, it can be mentioned that lung cancer mortality of the male population was 
substantially different among West and the former communist European countries, but nevertheless, 
the mortality rate remained the most frequent and highest in the age groups 65-74 and 75-84. 
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  Fig. 32- Mortality by age from lung cancer, EU countries, 1980, females 
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 Source: Author’s own calculation based on data from WHO mortality database   
 Fig. 33- Mortality by age from lung cancer, EU countries, 1990, females 
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 Fig. 34- Mortality by age from lung cancer, EU countries, 2006, females 
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  Notes: Belgium 2004, Portugal 2003, Slovakia 2005 
  Source: Author’s own calculation based on data from WHO mortality database   
According to Figure 32 it can be seen that development of lung cancer mortality among women was 
significantly low and quite homogeneous almost in all European countries. Mortality of the female 
population was the most frequent in the age groups of 55-64 and 65-74. Mortality patterns from lung 
cancer were significantly high in the United Kingdom, Denmark, Ireland, Hungary and the Czech 
Republic, while in France, Portugal and Spain they were considered low. 
Figure 33 shows that since 1990 development of lung cancer mortality soared in most of the 
Western European countries. For the age group 55-64 the highest mortality rate was in Denmark (14 
deaths per 100 000 women), while the minimal rate was recorded in Spain. In the age-group 65-74 
mortality rates were the highest in the United Kingdom (11 deaths per 100 000 women) and the 
lowest were in Spain. In all other age groups mortality was significantly low. 
The further development of lung cancer mortality can be considered as the most unfavorable. 
According to Figure 34, mortality level of the female population significantly increased in most of the 
European countries. It is important to note that lung cancer mortality was extraordinarily high and the 
most frequent among Danish women. In comparison to previous age groups, mortality from lung 
cancer significantly increased in Austria, Belgium, Slovenia, Germany, Sweden and the Czech 
Republic, while in Spain and Portugal it remeined low. In the other age groups (0-44, 45-54 and 85+) 
mortality level caused by lung cancer was lower, but nevertheless, in Hungary, Denmark and the 
Netherlands deaths rates remained significantly high. 
To conclude, it can be said that lung cancer affects elderly people most often. The highest 
rates of lung cancer mortality observed among seniors whose age is over 55 years. People younger 
than 45 years rarely suffer from this disease. Their share in the total mass of cancer patients is lower. 
Significant changes which were observed at the later stages of the epidemiological transition (for 
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example aging) can be directly linked to such factors as increased mortality from malignant 
neoplasms. Taking into account that lung cancer may develop in the middle rather than late ages, the 
elderly people remain to be the most vulnerable part of the population of the European countries. 
It has to be mentioned, that over the past few decades lung cancer mortality among the female 
population increased substantially, while men’s trends is gradually declining. Lung cancer is the 
exclusive form of neoplasm, which directly depends on smoking habits. Despite the numerous 
measures taken against smoking, tobacco consumption does not cease to decrease, it still remains one 
of the most popular and detrimental habits in some countries of the European Union (e.g. Denmark). 
Even in the countries where tobacco consumption is still low among women, many women's lives are 
already negatively affected by smoking, for example, through their husbands' spending scarce 
resources on cigarettes, their constant exposure to second-hand smoke and, increasingly, having to 
cope with a spouse's death from smoking. 
The challenge that the European Union countries face at the beginning of the 21st century is 
how to stop the female wave of the smoking epidemic, particularly in developed countries. There 
needs to be a wider recognition that women’s tobacco use is a global health and demographic problem 
and that effective women-centred tobacco control programmes should be implemented at international 
as well as national levels. Unless there is a strong, coordinated effort with the aims of preventing girls 
and adolescents from starting to smoke, and of assisting cessation, the tobacco epidemic will take a 
terrible toll on women (Mackay and Amos 2007:129).  
7.6. Hierarchical cluster analysis of mortality patterns caused by lung 
cancer 
The increasing trends of lung cancer mortality and other forms of malignant neoplasms in various 
countries of the European Union continues to be quite an urgent problem in the context of  the last 
two stages of the epidemiological transition. In order to identify mortality differentiation from lung 
cancer, we need to group the EU countries through a hierarchical cluster analysis.  
This part is devoted to study mortality tendencies of the male and female population of the 
 EU countries from lung cancer using hierarchical cluster analysis. The essence of hierarchical 
clustering is an organization of smaller clusters in large or breaking up large clusters into smaller 
ones. Interpretation of the clusters could be portrayed as a dendrogram. Results of hierarchical 
clustering are usually well represented as dendrogram which can accommodate a large amount of 
information in a relatively small space. Dendrogram describes the closeness of individual points and 
the clusters to each other, is a graphic sequence of the association (separation) clusters. It should be 
noted, that we are considering a horizontal tree diagram. The diagram starts with each object in the 
class (on the left side of the diagram). As these dendrograms indicat below, the horizontal axis 
represents the distance of group (in the vertical tree diagrams, the vertical axis represents the distance 
of unification). When the data have a clear "structure" in terms of clusters of objects that are similar to 
each other, then this structure is likely to be reflected in the hierarchical tree, by different branches. It 
is important to note, that according to the different clusters, we can determine what specific countries 
is the most prevailing or show significantly low level of mortality from lung cance. 
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Notes:  Selected years (1980-1984; 1991-1995; 2002-2006) 
Notes: Squared Euclidean distance, entry data transformed in Z-scores 
Source: Author’s calculations  
The result of the grouping the countries in a cluster analysis can be clearly seen in Figure 35. 
Specifically, the selected countries are divided into two basic groups and three subgroups. The first 
group consists of two countries like Portugal and Sweden which indicated below. According to 
previous analysis, development of lung cancer mortality among males considered to be low in Sweden 
and Portugal. All other countries belong to the second main group. The countries like Hungary, 
Poland, Belgium, the Czech Republic, the Netherlands, Slovakia and Slovenia belong to subgroup 
which can be considered as countries with high mortality. The second major subgroup consists mainly 
of Western European countries like Austria, Ireland, Finland, Denmark, Italy, Britain, France, Spain 
and Greece.  According to Subchapter 7.4, lung cancer mortality in these countries can be recorded as 
low.  
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Notes:  Selected years (1980-1984; 1991-1995; 2002-2006) 
Notes: Squared Euclidean distance, entry data transformed in Z-scores 
Source: Author’s calculations  
Figure 36 allows us to identify two main groups and three subgroups. The first group consists of the 
majority of Western and post-communist European countries, in which male mortality from lung 
cancer can be considered as significantly high. In contrast to the first group, the second group consists 
of a small number of countries (France, Greece, Bulgaria, Spain, Portugal, Romania and Sweden) 
where mortality among men was significantly lower than in the first group. The first subgroup 
includes such countries as Belgium, the Netherlands, the Czech Republic, Finland, the United 
Kingdom, Italy, Slovenia, Slovakia, Austria, Ireland and Denmark. The second subgroup mainly 
consists of the former socialist European countries; in particular Hungary, Poland and the Baltic 
States. According to the Chapter 7.4, it can be assumed that lung cancer mortality was relatively high 
in both subgroups. From the above-mentioned analysis, it can be seen that the differentiation between 
the clusters is fairly obvious, because all the countries belonging to certain groups and subgroups 
showed significantly different patterns in mortality from lung cancer. 
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Note:  Selected years (1980-1984; 1991-1995; 2002-2006) 
Note: Squared Euclidean distance, entry data transformed in Z-scores 
Source: Author’s calculations  
In contrast to cluster indicators that were observed among men on the previous dendrograms, different 
and more homogeneous trends among women can be distinguished. All the countries of the European 
Unioncan can be divided in two basic groups and three small subgroups. Countries such as Denmark, 
Ireland, Hungary and the United Kingdom belong to the first group, in which lung cancer mortality 
among women can be considered extremely high, whereas, all other countries belong to the second 
group. One of the main subgroup consists mainly of those countries (for instance: Bulgaria, Romania, 
Finland, Slovakia, Greece, Italy, France, Portugal, Spain and the Baltic States) where female mortality 
was significantly low. The second subgroup may differ significantly from the previous one, mortality 
patterns from lung cancer among women in countries like the Czech Republic, Poland, Belgium, 
Slovenia, Austria and the Netherlands were relatively high. 
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Note:  Selected years (1980-1984; 1991-1995; 2002-2006) 
Note: Squared Euclidean distance, entry data transformed in Z-scores 
Source: Author’s calculations  
According to Figure 38, distinct differences between the two main groups of clusters were observed. 
The first group which is located at the bottom of this figure consists of four countries of Western 
Europe (Ireland, the United Kingdom, Denmark and the Netherlands) where mortality development 
from lung cancer remains the most unfavorable. All other countries belong to the second group of 
clusters, which were divided in two distinct subgroups. In the first subgroup there are five countries 
(Portugal, Bulgaria, Latvia, Greece, Spain, and Lithuania) where mortality patterns can be considered 
as intense and high. Poland, Sweden, Belgium, the Czech Republic, Slovenia, France and Hungary 
belong to the second major subgroup with substantially high mortality level.  
  Thus, using hierarchical cluster analysis, the EU countries were determined and grouped in 
terms of lung cancer mortality. It allows to differentiate certain groups of countries with high and low 
levels of mortality trends.  
 






The analysis conducted in the Master Thesis covered 26 years (1980-2006) and presented the 
evidence of mortality development from lung cancer and other forms of malignant neoplasms in the 
European Union. The observed trends demonstrate that mortality trends still have substantial 
differences among most of the countries of the European Union. A comprehensive analysis of the part 
7.1 indicates that mortality development within cardiovascular diseases still remains the most frequent 
and wide-spread disease in comparison to malignant neoplasms. During 1980 and 2006 mortality 
trends from circulatory diseases significantly changed in many countries. Particularly, in 1980s male 
mortality was extraordinary high in Estonia, Hungry, Latvia, Poland and the Czech Republic. 
Comparatively low tendencies were recorded in Spain, Sweden and France. In subsequent years 
mortality trends were gradually declining in many Western European countries, while mortality has 
remained relatively high in many Eastern European countries. At the end of the 1990 mortality 
development from malignant neoplasms began to increase in many Western European countries. 
Nowadays cancer becomes one of the frequent causes of death among the European population. 
 The part 7.2 allows to define mortality development from neoplasms among male and female 
population. Mortality trends from neoplasms were substantially homogeneous in Western Europe. 
Initially, most of the countries had an extremely high mortality rates, (France, the Netherlands and 
Belgium). From the second half of the 1990 mortality from neoplasms significantly declined in 
Western Europe. In the post-communist countries (For instance: Hungary, Slovakia and Baltic States) 
mortality was exceptionally high and intense. Initially, male mortality in Romania and Bulgaria was 
relatively low, but in subsequent years it was considered to be high. As for women, mortality trends in 
Western Europe were rather heterogeneous. Neoplasm was the common cause of death among 
Danish, Irish and British women. In post-communist countries female mortality from cancer was 
extremely high in Hungary and the Czech Republic, while in other countries mortality was less 
intense. Over the past decade mortality trends in Western Europe changed in a positive direction 
(especially among men), while in the former socialist countries it continues to be high. There are 
many reasons according to which, one can argue about positive and negative reasons that influenced 
the development of cancer mortality. Firstly, these favorable trends were achieved due to the 
improvement of social infrastructure, increasing economical liberty and rising living standards. Also 
the following could be mentioned: improvement in early detection of neoplasms (screening), adopted 
strategies on national levels. Secondly, many important circumstances such as geographical location, 
political regime, living conditions as well as nutrition cultures are responsible for the shape of 
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mortality due to mentioned causes of death within the European Union countries. Thus, in many post-
communist countries of Europe (for example: Latvia, Lithuania, Estonia and Poland) mortality from 
neoplasms was very high and intense after the collapse and reformations that took place at the end of 
1980s.  
 Taking into account “supposed relation” between mortality and social stability within the 
concrete country, external exogenous factors that also play an important role must be taken into 
consideration. Industrial progress that has been emerging in most of European countries follows by 
pollution of air, all kinds of carcinogens that can negatively affect people’s life. It can be noted that 
natural and man-made disasters can cause long-term effects for human beings. The striking examples 
of human catastrophes are the Chernobyl accident and a breakdown in Fukusima Nuclear Station in 
Japan. In general, not only exogenous factors continue to adversely affect on vital activity of the 
population in European countries, but also, society itself faces many problems that have been hidden 
in our behavior. Such behavioral factors as poor diet, sedentary lifestyle, addiction to drinking alcohol 
beverages and tobacco dependence has led to the fact that people are increasingly suffering from 
cancer. Thus, guided by serious arguments, it can be said that deaths caused by malignant neoplasms 
in many countries of the European Union continue to be heterogeneous. Among the most frequent 
forms of malignant neoplasms, lung cancer remains the most common. A progressive growth of lung 
cancer mortality was recorded almost in all EU countries. In the United Kingdom, the Netherlands, 
the Czech Republic, Belgium and Hungary mortality development from neoplasms remains extremely 
high. During the past few decades, mortality from breast cancer was unusually high among the 
European women. At the end of 20th century this situation changed. Lung cancer became the 
prevailing cause of death among females particularly in Denmark, Hungary and the United Kingdom.   
 According to the Subchapter 7.4 it can be said that mortality development from lung cancer was 
very distinctive between West and post-communist Europe.  In 1980 West European countries faced a 
significant reduction from lung cancer mortality, while in post-communist Europe, mortality was 
considered to be high. From 1980 to 1987 the Netherlands and Belgium had the highest level of lung 
cancer mortality among men. Among the post-communist European countries Hungary had extremely 
high death rates. Mortality from lung cancer was substantially high in Poland, the Czech Republic and 
the Baltic States. One of the most favorable trends was recorded in France, Austria, Romania and 
Bulgaria, Sweden and Portugal. It is important to note that at the end of 1980 lung cancer mortality 
was gradually declining across West European countries, while in post-communist Europe mortality 
was increasing. In contrast to male trends, mortality development among women was substantially 
different. Throughout the entire period lung cancer mortality was very high in Denmark, the United 
Kingdom, Ireland, Hungary and the Netherlands.  One of the most favorable developments of the lung 
cancer mortality was observed for Spanish, Portuguese, French and Lithuanian women. The possible 
reason for disparity in mortality patterns among European countries is the difference in tobacco 
consumption. 
 The chapter 7.5 illustrates that lung cancer mortality mostly affected elderly people. According 
to the obtained results, it can be said that most of the seniors began to die after the age of 45. The 
most common in terms of lung cancer mortality is the age group 65-74. From 1980 to 1990, mortality 
among seniors was significantly high in the United Kingdom, Belgium, the Netherlands, and the 
Czech Republic. In 2006 it started to increase in the Baltic countries, Poland and Hungary as well. It 
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should be noted that mortality trends from lung cancer are significantly different between men and 
women. In 1980 lung cancer mortality was most common in the age group 45-54, but in 1990 and 
2006 it was observed to be high in the other age groups (for example 54-64, 65-74). Mortality among 
elderly women was extremely high in Denmark. Also, high mortality from lung cancer was recorded 
in the United Kingdom, Ireland, the Netherlands and Hungary.   
 According to the Chapter 6, it should be mentioned that there are many factors that may 
contribute to the emergence of lung cancer. It is important to note that lung cancer is related to 
domestic habits, environmental factors and lifestyle. Chemical and in particular radioactive substances 
such as radon and asbestos may have negative effect on lung tissue. Moreover, carcinogens as 
environmental and air pollution play their negative role in lung cancer emergence and development. 
All these factors are somehow connected with the external environment or occupational hazards. In 
contrast to the above-mentioned factors, tobacco smoking remains the most destructive and incredibly 
widespread habit.  Currently, tobacco smoking is a major risk factor for lung cancer. In addition, there 
is the possibility of inheriting the defective gene that is a genetic predisposition to malignant tumors. 
For example, certain genes influence a person's ability to absorb some of the carcinogenic chemicals 
contained in tobacco smoke. If a person with an inherited sensitivity starts to smoke, it may increase 
the risk of developing lung cancer compared to other smokers. Taking into account all risk factors that 
were mentioned above, it must be emphasized that a behavioral factor plays a key role in the 
avoidance of negative consequences carcinogens and rehabilitation.  As soon as people realize these 
negative factors, less people will suffer from this disease. 
 The obtained results allow to identify the countries with the highest level of cigarette 
consumption. According to gender differences described in Figures 1-2, it can be revealed that 
cigarette smoking among girls at age 15 was significantly high in Austria, Belgium, Latvia, Hungary 
and Germany. Among boys at the same age, smoking was most common in Austria, Spain, Finland, 
Denmark, Germany and the United Kingdom. Over the past two decades, cigarette smoking (among 
adult men and women) has substantially increased in many countries of the post-communist Europe 
(for example: Bulgaria, Hungary, Poland and the Baltic States), while in Western Europe smoking 
was gradually declining (for instance: Italy, France, Finland, Sweden and Portugal). It should be noted 
that by the end of the 1990s smoking prevalence was observed in Greece (the highest) as well in 
Spain and Slovenia. In contrast to Western European countries, where campaigns against tobacco 
smoking began earlier (e.g. increase of taxes, ban for advertising), tobacco products were much more 
accessible due to weak control for tobacco market and its cheapness and availability in the former 
socialist countries of Europe . 
 To conclude, it is difficult to predict the combined effect of mortality development from 
neoplasms in selected countries of the EU, because the trends differ so widely between countries 
according to age, sex and type of cancer. Undoubtedly, in particular countries of the European Union, 
for example Hungary, mortality from neoplasms still remains high for both sexes. However, it is 
important to emphasize, that many countries of the European Union (for instance: Belgium, the Czech 
Republic, Finland, France and the United Kingdom) have already made progress in their fight against 
cancer with more effective primary prevention, diagnosis and treatment. Effective implementation of 
further strategies in the future will help to limit the impact of many negative factors, in particular, 
strategies to reduce and offset tobacco consumption; effective screening for lung cancer; 
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mammography for breast and colorectal cancer, and adoption of the treatment that is proven to be 
effective and is accessible to all patients. It should be noted, that significance and priority for tobacco 
and cancer control can only be achieved with a high level of political support. In addition, a detailed 
analysis of the situation on the national level is a key step in implementing social policies against 
cancer. Scientists in the field of medicine and demography should facilitate further investigation of 
geographic and behavioral characteristics of diseases, mortality and survival for each of the most 
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